UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2026
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ____________ to _____________
Commission file number 001-37568
| | PDS Biotechnology Corporation | |
| | (Exact name of registrant as specified in its charter) | |
| Delaware | | 26-4231384 |
| (State or other jurisdiction of incorporation or organization) | | (IRS Employer Identification No.) |
| | 303A College Road East, Princeton, NJ 08540 | |
| | (Address of principal executive offices) | |
| | (800) 208-3343 | |
| | (Registrant’s telephone number) | |
| |
|
|
| |
(Former name, former address and former fiscal year, if changed since last report)
|
|
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | | Trading symbol(s) | | Name of each exchange on which registered |
| Common Stock, par value $0.00033 per share | | PDSB | | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the
definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ | Non-accelerated filer ☒ | Smaller Reporting Company ☒ |
| Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of shares of the registrant’s Common Stock, par value $0.00033 per share, outstanding as of November 5, 2026 was 105,005,429.
PDS BIOTECHNOLOGY CORPORATION
FORM 10-Q FOR THE QUARTER ENDED September 30, 2026
| |
|
|
Page
|
|
Part I — Financial Information
|
|
| |
|
|
|
| |
Item 1.
|
Financial Statements (Unaudited):
|
|
| |
|
|
|
| |
|
|
3 |
| |
|
|
|
| |
|
|
4
|
| |
|
|
|
| |
|
|
5
|
| |
|
|
|
| |
|
|
6
|
| |
|
|
|
| |
|
|
7
|
| |
|
|
|
| |
Item 2.
|
|
19 |
| |
|
|
|
| |
Item 3.
|
|
32 |
| |
|
|
|
| |
Item 4.
|
|
32 |
| |
|
|
|
|
Part II — Other Information
|
33 |
| |
|
|
|
| |
Item 1.
|
|
33 |
| |
|
|
|
| |
Item 1A.
|
|
33 |
| |
|
|
|
| |
Item 2.
|
|
52 |
| |
|
|
|
| |
Item 3.
|
|
52 |
| |
|
|
|
| |
Item 4.
|
|
52 |
| |
|
|
|
| |
Item 5.
|
|
52 |
| |
|
|
|
| |
Item 6.
|
|
52 |
| |
|
|
|
|
|
53 |
|
|
54 |
|
PART 1.
|
FINANCIAL INFORMATION
|
|
ITEM 1.
|
FINANCIAL STATEMENTS
|
PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY
Condensed Consolidated Balance Sheets
| |
|
September 30, 2026
|
|
|
December 31, 2025
|
|
|
ASSETS
|
|
(unaudited)
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
|
|
|
$
|
26,711,969 |
|
|
Prepaid expenses and other assets
|
|
|
3,128,550 |
|
|
|
1,542,116 |
|
|
Total current assets
|
|
|
18,373,631 |
|
|
|
28,254,085 |
|
| |
|
|
|
|
|
|
|
|
|
Noncurrent assets:
|
|
|
|
|
|
|
|
|
|
Prepaid expenses
|
|
|
- |
|
|
|
1,996,300 |
|
|
Property and equipment, net
|
|
|
168,225 |
|
|
|
120,184 |
|
|
Financing lease right-to-use assets
|
|
|
30,086 |
|
|
|
123,514 |
|
| |
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
18,571,942 |
|
|
$
|
30,494,083 |
|
| |
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
2,994,740 |
|
|
$
|
3,574,448 |
|
|
Accrued expenses
|
|
|
|
|
|
|
742,227 |
|
|
Current portion of debt
|
|
|
- |
|
|
|
5,130,372 |
|
|
Financing lease obligation-short term
|
|
|
32,427 |
|
|
|
36,167 |
|
|
Total current liabilities
|
|
|
|
|
|
|
9,483,214 |
|
| |
|
|
|
|
|
|
|
|
|
Noncurrent liabilities:
|
|
|
|
|
|
|
|
|
|
Debt, net of debt discount
|
|
|
- |
|
|
|
11,733,350 |
|
|
Financing lease obligation-long term
|
|
|
1,091 |
|
|
|
25,686 |
|
|
Total liabilities
|
|
$
|
|
|
|
$
|
21,242,250 |
|
| |
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Note 9)
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
| Common stock, $0.00033 par value, 300,000,000 and 150,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; 104,213,429 and 54,878,233 issued and outstanding at September 30, 2026 and December 31, 2025, respectively |
|
|
34,391 |
|
|
|
18,111 |
|
|
Additional paid-in capital
|
|
|
254,787,809 |
|
|
|
225,840,226 |
|
|
Accumulated deficit
|
|
|
(241,327,060 |
)
|
|
|
(216,606,504 |
)
|
|
Total stockholders’ equity
|
|
|
13,495,140 |
|
|
|
9,251,833 |
|
| |
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders’ equity
|
|
$
|
18,571,942 |
|
|
$
|
30,494,083 |
|
See accompanying notes to the condensed consolidated financial statements.
PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY
Condensed Consolidated Statements of
Operations and Comprehensive Loss
(Unaudited)
| |
|
Three Months Ended September 30,
|
|
|
Nine Months Ended September 30,
|
|
| |
|
2026
|
|
|
2025
|
|
|
2026
|
|
|
2025 |
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income (expense), net
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Benefit from income taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss and comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share, basic and diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding, basic, and diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to the condensed consolidated financial statements.
PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY
Condensed Consolidated Statements of
Changes in Stockholders’ Equity
(Unaudited)
| |
|
Common Stock
|
|
|
Additional
|
|
|
Accumulated
|
|
|
|
|
| |
|
Shares Issued
|
|
|
Amount
|
|
|
Paid-in Capital
|
|
|
Deficit
|
|
|
Total Equity
|
|
|
January 1, 2025
|
|
|
37,987,380 |
|
|
$
|
12,536 |
|
|
$
|
201,103,311 |
|
|
$
|
(182,110,999 |
)
|
|
$
|
19,004,848 |
|
|
Stock-based compensation expense
|
|
|
-
|
|
|
|
- |
|
|
|
1,253,882 |
|
|
|
- |
|
|
|
1,253,882 |
|
|
Issuance of common stock for consulting agreement
|
|
|
150,000 |
|
|
|
50 |
|
|
|
203,451 |
|
|
|
- |
|
|
|
203,501 |
|
|
Issuance of common stock from at-the-market program, net
|
|
|
205,350 |
|
|
|
68 |
|
|
|
306,047 |
|
|
|
- |
|
|
|
306,115 |
|
|
Issuances of common stock, net of issuance costs
|
|
|
6,396,787 |
|
|
|
2,111 |
|
|
|
6,919,908 |
|
|
|
- |
|
|
|
6,922,019 |
|
|
Issuance of pre-funded warrants
|
|
|
-
|
|
|
|
- |
|
|
|
1,009,969 |
|
|
|
- |
|
|
|
1,009,969 |
|
|
Issuance of warrants
|
|
|
-
|
|
|
|
- |
|
|
|
2,150,771 |
|
|
|
- |
|
|
|
2,150,771 |
|
|
Exercise of pre-funded warrants
|
|
|
706,334 |
|
|
|
233 |
|
|
|
(162 |
)
|
|
|
- |
|
|
|
71 |
|
|
Net loss
|
|
|
-
|
|
|
|
- |
|
|
|
- |
|
|
|
(8,488,967 |
)
|
|
|
(8,488,967 |
)
|
|
Balance - March 31, 2025
|
|
|
45,445,851 |
|
|
$
|
14,998 |
|
|
$
|
212,947,177 |
|
|
$
|
(190,599,966 |
)
|
|
$
|
22,362,209 |
|
|
Stock-based compensation expense
|
|
|
-
|
|
|
|
- |
|
|
|
448,029 |
|
|
|
- |
|
|
|
448,029 |
|
|
Issuance of common stock from at-the-market program, net
|
|
|
960,511 |
|
|
|
317 |
|
|
|
1,460,325 |
|
|
|
- |
|
|
|
1,460,642 |
|
|
Issuances of common stock, net of issuance costs
|
|
|
- |
|
|
|
- |
|
|
|
50,000 |
|
|
|
- |
|
|
|
50,000 |
|
|
Issuance of warrants
|
|
|
-
|
|
|
|
- |
|
|
|
1,073,089 |
|
|
|
- |
|
|
|
1,073,089 |
|
|
Exercise of pre-funded warrants
|
|
|
227,000 |
|
|
|
75 |
|
|
|
(52 |
)
|
|
|
- |
|
|
|
23 |
|
|
Net loss
|
|
|
-
|
|
|
|
- |
|
|
|
- |
|
|
|
(9,434,208 |
)
|
|
|
(9,434,208 |
)
|
|
Balance - June 30 , 2025
|
|
|
46,633,362 |
|
|
$
|
15,390 |
|
|
$
|
215,978,568 |
|
|
$
|
(200,034,174 |
)
|
|
$
|
15,959,784 |
|
|
Stock-based compensation expense
|
|
|
-
|
|
|
|
- |
|
|
|
1,246,485 |
|
|
|
- |
|
|
|
1,246,485 |
|
|
Issuance of common stock from at-the-market program, net
|
|
|
1,072,080 |
|
|
|
354 |
|
|
|
1,256,298 |
|
|
|
- |
|
|
|
1,256,652 |
|
|
Net loss
|
|
|
-
|
|
|
|
- |
|
|
|
- |
|
|
|
(9,009,411 |
)
|
|
|
(9,009,411 |
)
|
|
Balance - September 30, 2025
|
|
|
47,705,442 |
|
|
$
|
15,744 |
|
|
$
|
218,481,351 |
|
|
$
|
(209,043,585 |
)
|
|
$
|
9,453,510 |
|
| |
|
Common Stock
|
|
|
Additional
|
|
|
Accumulated
|
|
|
|
|
| |
|
Shares Issued
|
|
|
Amount
|
|
|
Paid-in Capital
|
|
|
Deficit
|
|
|
Total Equity
|
|
|
January 1, 2026
|
|
|
54,878,233 |
|
|
$
|
18,111 |
|
|
$
|
225,840,226 |
|
|
$
|
(216,606,504 |
)
|
|
$
|
9,251,833 |
|
|
Stock-based compensation expense
|
|
|
-
|
|
|
|
- |
|
|
|
1,156,495 |
|
|
|
- |
|
|
|
1,156,495 |
|
|
Issuance of common stock for consulting agreement
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Issuance of common stock from at-the-market program, net
|
|
|
937,420 |
|
|
|
309 |
|
|
|
833,062 |
|
|
|
- |
|
|
|
833,371 |
|
|
Issuances of common stock, net of issuance costs
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Issuance of pre-funded warrants
|
|
|
-
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Issuance of warrants
|
|
|
-
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Exercise of pre-funded warrants
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Net loss
|
|
|
-
|
|
|
|
- |
|
|
|
- |
|
|
|
(7,349,056 |
)
|
|
|
(7,349,056 |
)
|
|
Balance - March 31, 2026
|
|
|
55,815,653 |
|
|
$
|
18,420 |
|
|
$
|
227,829,783 |
|
|
$
|
(223,955,560 |
)
|
|
$
|
3,892,643 |
|
|
Stock-based compensation expense
|
|
|
-
|
|
|
|
- |
|
|
|
1,126,054 |
|
|
|
- |
|
|
|
1,126,054 |
|
|
Issuance of common stock from at-the-market program, net
|
|
|
106,153 |
|
|
|
35 |
|
|
|
97,196 |
|
|
|
- |
|
|
|
97,231 |
|
|
Issuances of common stock, net of issuance costs
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Issuance of warrants
|
|
|
-
|
|
|
|
- |
|
|
|
1,054,908 |
|
|
|
- |
|
|
|
1,054,908 |
|
|
Exercise of pre-funded warrants
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
Net loss
|
|
|
-
|
|
|
|
- |
|
|
|
- |
|
|
|
(9,750,575 |
)
|
|
|
(9,750,575 |
)
|
|
Balance - June 30 , 2026
|
|
|
55,921,806 |
|
|
$
|
18,455 |
|
|
$
|
230,107,941 |
|
|
$
|
(233,706,135 |
)
|
|
$
|
(3,579,739 |
)
|
|
Stock-based compensation expense
|
|
|
-
|
|
|
|
- |
|
|
|
840,221 |
|
|
|
- |
|
|
|
840,221 |
|
|
Issuance of common stock from at-the-market program, net
|
|
|
31,788,753 |
|
|
|
10,490 |
|
|
|
12,538,451 |
|
|
|
- |
|
|
|
12,548,941 |
|
|
Issuances of common stock, net of issuance costs
|
|
|
16,502,870 |
|
|
|
5,446 |
|
|
|
2,502,486 |
|
|
|
- |
|
|
|
|
|
Issuance of pre-funded warrants
|
|
|
-
|
|
|
|
- |
|
|
|
3,568,052 |
|
|
|
- |
|
|
|
3,568,052 |
|
| Issuance of common stock warrants |
|
|
-
|
|
|
|
- |
|
|
|
1,761,818 |
|
|
|
- |
|
|
|
1,761,818 |
|
Issuance of contingent milestone commitment
|
|
|
-
|
|
|
|
- |
|
|
|
3,462,488 |
|
|
|
- |
|
|
|
3,462,488 |
|
|
Issuance of warrants - adjustment
|
|
|
-
|
|
|
|
- |
|
|
|
6,352 |
|
|
|
- |
|
|
|
6,352 |
|
|
Net loss
|
|
|
-
|
|
|
|
- |
|
|
|
- |
|
|
|
(7,620,925 |
)
|
|
|
(7,620,925 |
)
|
|
Balance - September 30, 2026
|
|
|
104,213,429 |
|
|
$
|
34,391 |
|
|
$
|
254,787,809 |
|
|
$
|
(241,327,060 |
)
|
|
$
|
13,495,140 |
|
See accompanying notes to the condensed consolidated financial statements.
PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY
Condensed Consolidated Statements of
Cash Flows
(Unaudited)
| |
|
Nine Months Ended September 30, |
|
| |
|
2026 |
|
|
2025 |
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(24,720,556 |
)
|
|
$
|
(26,932,586 |
)
|
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
|
Stock-based compensation expense
|
|
|
3,122,770 |
|
|
|
2,948,396 |
|
|
Issuance of shares in consulting agreements
|
|
|
- |
|
|
|
203,501 |
|
|
Amortization of debt discount
|
|
|
1,261,972 |
|
|
|
1,079,427 |
|
|
Loss on retirement of debt
|
|
|
3,766,112 |
|
|
|
752,838 |
|
|
Depreciation expense
|
|
|
22,233 |
|
|
|
16,377 |
|
|
Finance lease depreciation expense
|
|
|
23,154 |
|
|
|
29,010 |
|
|
Changes in assets and liabilities:
|
|
|
|
|
|
|
|
|
|
Prepaid expenses and other assets
|
|
|
409,866 |
|
|
|
(4,883,470 |
)
|
|
Accounts payable
|
|
|
(579,708 |
)
|
|
|
3,496,060 |
|
|
Accrued expenses
|
|
|
1,306,317 |
|
|
|
(758,980 |
)
|
|
Net cash used in operating activities
|
|
|
(15,387,840 |
)
|
|
|
(24,049,427 |
)
|
| |
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
Proceeds from exercise of pre-funded warrants
|
|
|
- |
|
|
|
94 |
|
|
Proceeds from issuance of warrants
|
|
|
1,061,260 |
|
|
|
2,150,771 |
|
|
Payments of finance lease obligations
|
|
|
(28,335 |
)
|
|
|
(45,313 |
)
|
|
Loan principal payment
|
|
|
(2,500,000 |
)
|
|
|
(5,166,667 |
)
|
|
Loan repayment
|
|
|
(17,738,889 |
)
|
|
|
(18,645,833 |
)
|
|
Net proceeds from issuance of debt
|
|
|
4,347,083 |
|
|
|
19,237,884 |
|
|
Loan repayment
|
|
|
(6,000,000 |
)
|
|
|
- |
|
|
Proceeds from issuance of common stock from at-the-market program, net of issuance costs
|
|
|
13,479,543 |
|
|
|
3,023,409 |
|
|
Proceeds from issuance of common stock, net of issuance costs
|
|
|
2,507,932 |
|
|
|
6,994,174 |
|
|
Proceeds from issuance of pre-funded warrants
|
|
|
3,568,052 |
|
|
|
1,009,969
|
|
|
Proceeds from issuance of common stock warrants
|
|
|
1,761,818 |
|
|
|
- |
|
|
Proceeds from allocation to contingent milestone commitment
|
|
|
3,462,488 |
|
|
|
- |
|
|
Net cash provided by financing activities
|
|
|
3,920,952 |
|
|
|
8,558,488 |
|
| |
|
|
|
|
|
|
|
|
|
Net decrease in cash and cash equivalents
|
|
|
(11,466,888 |
)
|
|
|
(15,490,939 |
)
|
|
Cash and cash equivalents at beginning of period
|
|
|
26,711,969 |
|
|
|
41,689,591 |
|
| |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at the end of period
|
|
$
|
15,245,081 |
|
|
$
|
26,198,652 |
|
| |
|
|
|
|
|
|
|
|
|
Supplemental information of cash and non-cash transactions:
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
1,645,831 |
|
|
$
|
2,284,553 |
|
See accompanying notes to the condensed consolidated financial statements.
PDS BIOTECHNOLOGY CORPORATION AND SUBSIDIARY
Notes to Condensed Consolidated Financial Statements (Unaudited)
Note 1 – Nature of Operations
PDS Biotechnology Corporation, a Delaware corporation (the “Company” or “PDS Biotech”), is a clinical-stage biotechnology company focused on developing PDS0301 (formerly
PDS01ADC), a tumor-targeted IL-12 immunocytokine designed to modify the tumor microenvironment and enhance the activity and durability of anti-cancer therapies. The Company’s current development strategy prioritizes PDS0301, including its
development in colorectal cancer and evaluation in other combinations and as a monotherapy.
The Company also develops its proprietary Versamune® platform for treatments in oncology and Infectimune® for treatments in infectious diseases. The most advanced Versamune® drug
candidate, PDS0101, has been evaluated in multiple clinical trials with promising results, and the Company seeks to further the development of PDS0101 through strategic partnerships. In August 2026, the Company discontinued its Phase 3 trial with
PDS0101 in HPV16-positive recurrent/metastatic head and neck cancer.
Note 2 – Summary of Significant Accounting Policies
| (A) | Unaudited interim financial statements: |
The unaudited financial statements for all periods presented are referred to as “Condensed Consolidated Financial Statements”, and have been prepared by the Company in United States
(“U.S.”) dollars and in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and pursuant to the rules and regulations for reporting on Form 10-Q, which do not conform in all respects to the
requirements of U.S. GAAP for annual financial statements. Accordingly, certain information and disclosures required by U.S. GAAP for complete Consolidated Financial Statements are not included herein. Accordingly, these notes to the unaudited
Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements prepared in accordance with U.S. GAAP that are contained in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2025, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 30, 2026, as amended by Amendment No.1 on Form 10-K/A filed April 28, 2026. The unaudited Condensed Consolidated Financial Statements have been prepared
using accounting policies that are consistent with the policies used in preparing the Company’s audited consolidated financial statements for the year ended December 31, 2025. The unaudited Condensed Consolidated Financial Statements reflect all
normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the
results expected for the full year or for any other subsequent interim period.
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the reported amounts of expenses at the date of the consolidated financial statements and during the reporting periods, and to disclose contingent assets and liabilities at the date of the consolidated financial
statements. Actual results could differ from those estimates. The most significant estimates relate to the fair value of warrants issued in connection with equity and/or debt financings and the fair value of securities underlying stock-based
compensation.
| (C) | Significant risks and uncertainties: |
The Company’s operations are subject to a number of factors that may affect its operating results and financial condition. Such factors include, but are not limited to: the
clinical and regulatory development of its products, the Company’s ability to preserve its cash resources, the Company’s ability to add product candidates to its pipeline, risks related to the Company’s intellectual property, the Company’s
ability to complete clinical trials necessary to obtain regulatory product licenses, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products if approved for sale, the
Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital.
The Company currently has no commercially approved products. As such, there can be no assurance that the Company’s future research and development programs will be
successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company
operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting its intellectual property.
| (D) | Cash equivalents and concentration of cash balance: |
The Company considers all highly liquid securities with a maturity of less than three months to be cash equivalents. The Company’s cash and cash equivalents in bank deposit
accounts, at times, may exceed federally insured limits.
| (E) | Research and development: |
Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s
research and development projects as well as fees paid to consultants and vendors that perform certain research activities and testing on behalf of the Company.
Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data, such as patient
enrollment, clinical site activations or information provided by vendors about their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the timing and pattern of costs
incurred.
The Company expenses patent costs as incurred and classifies such costs as general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations
and Comprehensive Loss.
| (G) | Stock-based compensation: |
The Company accounts for its stock-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). ASC
718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss based on their grant date fair values. In order to determine
the fair value of stock options on the date of grant, the Company uses the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected stock-price volatility, option term, risk-free interest rate and dividend
yield. While the risk-free interest rate and dividend yield are less subjective assumptions that are based on factual data derived from public sources, the expected stock-price volatility and option term assumptions require a greater level of
judgment. The Company expenses the fair value of its stock-based compensation awards to employees and directors on a straight-line basis over the requisite service period, which is generally the vesting period. The Company recognizes forfeitures as
they occur.
| (H) | Net loss per common share: |
Basic and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted average number of common stock shares and
pre-funded warrants outstanding during the period. Shares of common stock into which the pre-funded warrants may be exercised are considered outstanding for the purposes of computing net loss per share because the shares may be issued for little or
no consideration, are fully vested, and are exercisable after the original issuance date. For all periods presented, the common stock shares underlying the stock options and warrants have been excluded from the calculation because their effect
would be antidilutive. Therefore, the weighted average shares outstanding used to calculate both basic and diluted loss per common share is the same.
The potentially dilutive securities excluded from the determination of diluted loss per share as their effect is antidilutive, are as follows:
| |
|
As of September 30,
|
|
| |
|
2026
|
|
|
2025
|
|
|
Stock options to purchase common stock
|
|
|
6,808,233 |
|
|
|
7,196,088 |
|
|
Performance-based restricted stock units
|
|
|
600,000 |
|
|
|
- |
|
|
Warrants to purchase common stock
|
|
|
|
|
|
|
8,757,034 |
|
|
Total
|
|
|
|
|
|
|
15,953,122 |
|
The Company makes provision for deferred income taxes under the asset and liability method, which requires deferred tax assets and liabilities to be recognized for the future tax
consequences attributable to net operating loss carryforwards and for differences between the financial statement carrying amounts and the respective tax bases of assets and liabilities. Deferred tax assets are reduced, if necessary, by a
valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.
| (J) | Convertible debentures and embedded derivative evaluation: |
The Company accounts for its convertible debentures in accordance with ASC Subtopic 470-20, Debt–Debt with Conversion and Other Options, ASC Subtopic 815-40, Derivatives and Hedging–Contracts in Entity’s Own Equity and ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.
The Company evaluates the terms of its debt instruments to determine if any identified embedded features, including embedded conversion options or redemption features, are required to be bifurcated and accounted for separately as a
derivative financial instrument. In circumstances where a host instrument contains more than one embedded derivative instrument, including a conversion option, that is required to be bifurcated, the bifurcated derivative instruments
would be accounted for as a single, compound derivative instrument. Any identified and bifurcated embedded derivatives are initially recorded at fair value and are revalued at each reporting date with changes in the fair value
reported as non-operating income or expense.
| (K) | Warrants to acquire common stock: |
The Company accounts for common stock warrants as either equity classified or liability classified instruments based on an assessment of the warrant’s specific terms and
applicable authoritative guidance in ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC Topic 815, Derivatives and Hedging (“ASC 815”). The
assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether the warrants meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity
classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among
other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and is reassessed at each reporting date while the warrants remain outstanding.
| (L) | Fair value of financial instruments: |
FASB ASC 820, Fair Value Measurement, specifies a hierarchy of valuation techniques based on whether the inputs to those valuation
techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in
active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).
The three levels of the fair value hierarchy are as follows:
|
● |
Level 1 — Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial
instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.
|
|
● |
Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active
markets, or quoted prices for identical or similar assets or liabilities in markets that are not active). Level 2 includes financial instruments that are valued using models or other valuation methodologies.
|
|
● |
Level 3 — Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques
and at least one significant model assumption or input is unobservable.
|
The Company determines if an arrangement is a lease at inception and recognizes the lease in accordance with ASC 842, Leases (“ASC 842”). Both financing
and operating leases are included in right-of-use (“ROU”) assets, lease obligation-short term and lease obligation-long term in the Company’s Condensed Consolidated Balance Sheets. ROU assets represent the right to use an underlying asset for the
lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the lease payments
over the lease term. The Company determines the portion of the lease liability that is current as the difference between the calculated lease liability at the end of the current period and the lease liability that is projected 12 months from the
current period.
| (N) | New accounting standards: |
Recent Accounting Pronouncements Not Yet Adopted
In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The new guidance requires a public business entity to provide disaggregated disclosures, in the notes to the financial statements, of certain
categories of expenses that are included in expense line items on the face of the consolidated statements of operations and comprehensive loss. The amendments in this update are effective for annual reporting periods beginning after December 15,
2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that the new guidance will have on its consolidated financial statements.
Note 3 – Liquidity and Capital Resources
As of September 30, 2026, the Company had $15.2 million in cash and cash equivalents. The Company’s primary uses of cash are to fund operating expenses, primarily research and development and general and administrative expenditures. Since inception, the Company has no revenue, has experienced net losses and negative operating cash flows and expects to continue to incur operating losses for the foreseeable future.
The Company funds its operations through equity and/or debt financings such as the following:
In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company could offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50 million, or the Placement Shares, through or to the Agents, as sales agents or principals. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents could sell the Placement Shares by any method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market for the Company’s common stock. The Agents were to use commercially reasonable efforts to sell the Placement Shares from time to time, based upon the Company’s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company paid the Agents a commission equal to three percent (3%) of the gross sales proceeds of any Placement Shares sold through the Agents under the Sales Agreement, and the Company has also provided the Agents with customary indemnification and contribution rights. The Company was not obligated to make any sales of its common stock under the Sales Agreement. The offering of Placement Shares pursuant to the Sales Agreement was to terminate upon the earlier of (i) the sale of all Placement Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms.
In August 2024, the Company entered into an Amended and Restated At Market Issuance Sales Agreement, or the New Sales Agreement, with B. Riley Securities, Inc. and H.C. Wainwright
& Co., LLC, with terms that are substantially consistent with those included in the original Sales Agreement. The New Sales Agreement superseded and replaced the Sales Agreement.
During the three and nine months ended September 30, 2026, the Company sold 0 shares and 937,420 shares, respectively, of its common stock with a net value of $0 million and $0.8 million, respectively, pursuant to the New Sales Agreement. During the three and nine months ended September 30, 2025, the Company sold 1,072,080 and 2,237,941 shares, respectively, of its common stock with a net value of $1.3 and $3.0 million, respectively, pursuant to the New Sales Agreement. The New Sales Agreement was terminated on May 1, 2026.
In June 2026, we entered into a Sales Agreement, or the June 2026 Sales Agreement with Yorkville Securities, LLC and B. Riley Securities, Inc., with terms that are substantially consistent with those included in the New Sales Agreement. During the three and nine months ended September 30, 2026, the Company sold 31,788,753 and 31,894,906 shares of common stock, respectively, for a net value of $12.64 million and $12.74 million, respectively, pursuant to the June 2026 Sales Agreement.
In August 2022, the Company entered into a venture loan and security agreement, or the Loan and Security Agreement, with Horizon Technology Finance Corporation, as lender and collateral agent for itself and the other lenders. In total, the Company received $24.6 million in net proceeds under the Loan and Security Agreement. The Company’s indebtedness under the Loan and Security Agreement was satisfied in full and retired in full with a portion of the proceeds received from the Securities Purchase Agreement, as discussed below.
In January and February 2025, the Company received approximately $1.2 million from the net sale of tax benefits to two unrelated, profitable New Jersey corporations pursuant to its participation in the New Jersey Technology Business Tax Certificate Transfer NOL program for tax year 2023.
In February 2025, the Company entered into a securities purchase agreement with certain purchasers, pursuant to which the Company agreed to sell an aggregate of 6,396,787 shares of common stock, pre-funded warrants to purchase up to an aggregate of 933,334 shares of common stock, and common stock warrants to purchase up to an aggregate of 7,330,121 shares of common stock at a combined purchase price of $1.50 per share and warrant (the “February 2025 Offering”). Two of the Company’s directors participated in the February 2025 Offering and purchased 30,121 shares of common stock in the aggregate at an offering price per share of $1.66 and common stock warrants to purchase 30,121 shares of common stock. The common stock warrants issued to the Company’s directors have an exercise price per share of $1.53 but are otherwise identical to the common stock warrants issued to all other participants in the February 2025 Offering. Aggregate gross proceeds from the February 2025 Offering were approximately $11 million. Net proceeds to the Company from the February 2025 Offering, after deducting the placement agent fees and other estimated offering expenses payable by the Company, were approximately $10.05 million. The placement agent fees and offering expenses were accounted for as a reduction of additional paid in capital. The February 2025 Offering closed on February 28, 2025.
In April 2025, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain third-party lenders and JGB Collateral LLC, as collateral agent. Pursuant to the Securities Purchase Agreement, the Company agreed to sell (i) senior secured convertible debentures in an aggregate principal amount of $22.2 million (collectively, the “Debentures”) and (ii) warrants to purchase up to 1,000,000 shares of common stock, for an exercise price of $2.52 per share (collectively, the “Warrants”), subject to adjustments as set forth in the Warrants, for a total purchase price of $20.0 million. Approximately $19 million of the proceeds from the transactions contemplated by the Securities Purchase Agreement, were used to satisfy in full and retire the Company’s indebtedness under the Loan and Security Agreement. On April 30, 2026, the Company delivered a redemption notice pursuant to which it irrevocably elected to prepay, for cash, all of the outstanding principal amount under each of the Debentures issued pursuant to the Securities Purchase Agreement. On June 15, 2026, the Company paid the applicable redemption amount, equal to 103% of the principal amount outstanding plus all accrued and unpaid interest and all other amounts payable thereunder, and, upon such payment, each Debenture was redeemed in full and is of no further force or effect.
In November 2025, the Company entered into a securities purchase agreement with certain purchasers, pursuant to which the Company agreed to sell an aggregate of 5,741,000 shares of common stock, pre-funded warrants to purchase up to an aggregate of 59,000 shares of common stock, and common stock warrants to purchase up to an aggregate of 5,800,000 shares of common stock (the “November 2025 Offering”). The November 2025 offering price per share of common stock was $0.91 and the purchase price of each pre-funded warrant was $0.9099. Each common warrant issued in connection with the November 2025 Offering had an exercise price of $1.00 per share, can be exercised six months after the date of issuance and will expire five years thereafter. Aggregate gross proceeds from the November 2025 Offering were $5.3 million. Net proceeds to the Company from the offering, after deducting the placement agent fees and other estimated offering expenses payable by the Company, were approximately $4.8 million. The November 2025 Offering closed on November 12, 2025.
On April 30, 2026, the Company entered into a securities purchase agreement (the “April 2026 Securities Purchase Agreement”) with YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”). Pursuant to the securities purchase agreement, the Company agreed to issue and sell to the Investor and the Investor agreed to purchase from the Company (i) a promissory note in an aggregate principal amount of $6,000,000 (the “Promissory Note”) and (ii) a warrant to purchase up to 2,158,274 shares of common stock of the Company, par value $0.00033 per share, at an exercise price of $1.1824 per share, subject to adjustments (the “Warrant”). In addition, on June 15, 2026, in connection with the transactions contemplated by the April 2026 Securities Purchase Agreement, the Company issued the Promissory Note and the Warrant to the Investor, the Company and the Investor entered into the Registration Rights Agreement and PDS Operating Corporation, a Delaware corporation and wholly owned subsidiary of the Company and the Investor entered into a guaranty agreement.
On June 15, 2026, the Company entered into a Sales Agreement (the “June 2026 Sales Agreement”) with Yorkville Securities, LLC, an affiliate of the Investor (“Yorkville Securities”), and B. Riley Securities, Inc. (“B. Riley Securities,” each of Yorkville Securities and B. Riley Securities individually an “Agent” and collectively, the “Agents”), with terms that are substantially consistent with those included in the New Sales Agreement, with respect to an “at-the-market” offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its Common Stock (the “Placement Shares”) having an aggregate offering price of up to $50,000,000 through or to the Agents, as sales agents or principals. Yorkville Securities is an affiliate of the Investor. The issuance and sale, if any, of the Placement Shares by the Company under the June 2026 Sales Agreement will be made pursuant to the Company’s registration statement on Form S-3 (File No. 333-289942), which was declared effective by the SEC on April 28, 2026, and a prospectus supplement relating to the Placement Shares filed with the SEC. During the three and nine months ended September 30, 2026, the Company sold 31,788,753 and 31,894,906 shares of common stock, respectively, for a net value of $12.64 million and $12.74 million, respectively, pursuant to the June 2026 Sales Agreement.
On September 7, 2026, the Company entered into a securities purchase agreement (the “September 2026 Purchase Agreement”) with certain accredited investors, including Nant Capital, LLC (”Nant”) and AB Group Ltd. (“AB Group”), providing for a private placement consisting of an initial closing and a contingent milestone closing (the “September 2026 Private Placement”). By virtue of its significant post-transaction equity and warrant holdings and its contractual board designation rights described below, Nant is considered a related party of the Company in accordance with ASC Topic 850, Related Party Disclosures. At the initial closing on September 14, 2026, the Company issued 16,502,870 shares of common stock, pre-funded warrants to purchase up to 23,498,156 shares of common stock (the “September Pre-Funded Warrants”), and common stock warrants to purchase up to 20,000,514 shares of common stock (the “September Common Warrants”), for aggregate gross proceeds of approximately $11.3 million. Each unit consisting of one share of common stock and an accompanying warrant to purchase one-half of one share of common stock was sold for $0.2825. Each unit consisting of one September Pre-Funded Warrant and an accompanying warrant to purchase one-half of one share of common stock was sold for $0.28217. The September Pre-Funded Warrants have an exercise price of $0.00033 per share and remain exercisable until exercised in full and are subject to a nonwaivable 19.99% beneficial ownership limitation. The September Common Warrants have an exercise price of $0.22 per share, are exercisable from issuance through the first anniversary of issuance and are subject to the nonwaivable 19.9% beneficial ownership limitation. The September Common Warrants also provide for cashless exercise under certain circumstances and permit holders to receive pre-funded warrants in lieu of common stock when the beneficial ownership limitation prevents the issuance of common shares.
The contingent milestone closing is triggered upon the Company’s submission to the U.S. Food and Drug Administration of a registrational Phase 3 clinical trial protocol for PDS0301 designed in collaboration with Nant, subject to satisfaction or waiver of applicable closing conditions. Nant and AB Group are obligated to invest an additional $10 million and $1 million, respectively, at a price of $0.22 per share of common stock or $0.21967 per pre-funded warrant. Under the September 2026 Purchase Agreement, Nant has the right to designate two directors while it beneficially owns at least 15% of the Company’s outstanding common stock and one director while it beneficially owns at least 5% of the Company’s outstanding common stock, subject to the September 2026 Purchase Agreement. These board appointment rights confer significant influence over the Company’s governance, operating policies, and strategic clinical directions. The Company also entered into a registration rights agreement with the investors and an option agreement with NantWorks, LLC, (“NantWorks”), an affiliate under common control with Nant (and therefore also a related party under ASC Topic 850), for an upfront option fee of $25,000, as described in Note 9.
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization
of assets and the settlement of liabilities and commitments in the normal course of business.
The Company evaluated whether conditions and events, considered in the aggregate, raise substantial doubt about its ability to continue as a going
concern within one year after the filing of this Quarterly Report on Form 10-Q in accordance with ASC Subtopic 205-40, Going Concern. Since inception, the Company has had no revenue, has experienced net
losses and negative operating cash flows, and expects to continue to incur operating losses for the foreseeable future. In previous periods, and as recently as the quarter ended June 30, 2026, the Company had determined that substantial doubt about
the Company’s ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However, following completion of the September 2026 Private Placement, exercise of
additional warrants, and its cost-reduction initiatives, described below, management believes the Company’s cash and cash equivalents will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of
these condensed consolidated financial statements and as such substantial doubt has been alleviated.
The Company received approximately $11.3 million in gross proceeds at the initial closing of the September 2026 Private Placement, repaid the Yorkville promissory note on September 14, 2026, and received additional proceeds from its existing at-the-market facility ($0.7 million) and the exercise of outstanding warrants ($3.9 million) in November 2026 (see Note 15), which mitigated the Company’s funding needs. The Company also implemented certain cost-saving initiatives including the reduction of research and development expenses related to ending its Phase 3 clinical trial with PDS0101, as well as certain general and administrative expenses. While the contingent milestone closing described earlier is expected to occur in advance of the December 31, 2026 fiscal year-end, this is not within the Company’s control and therefore, were the milestone not to be achieved, the Company intends to pause its research and development activities until additional financing is obtained.
The Company expects to continue to fund its operations through available cash, additional equity or debt financing, collaborations, strategic alliances
or license agreements. However, there can be no assurance that the milestone and applicable conditions will be satisfied or that other financing will be available when needed on acceptable terms. If sufficient funding is not available, the Company
may be required to delay, reduce or discontinue development programs or other operations.
The financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be
necessary if the Company is unable to continue as a going concern.
Note 4 – Fair Value of Financial Instruments
There were no transfers between Levels 1, 2, or 3 during the three months ended September 30, 2026 or 2025.
| |
|
Fair Value Measurements at Reporting Date Using
|
|
| |
|
Total
|
|
|
Quoted Prices in
Active Markets
(Level 1)
|
|
|
Quoted Prices in
Inactive Markets
(Level 2)
|
|
|
Significant
Unobservable Inputs
(Level 3)
|
|
|
As of September 30, 2026: (unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
15,245,081 |
|
|
$
|
15,245,081 |
|
|
$
|
– |
|
|
$
|
– |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
26,711,969 |
|
|
$
|
26,711,969 |
|
|
$
|
– |
|
|
$
|
– |
|
The Promissory Note was repaid in full on September 14, 2026 and no amounts were outstanding as of September 30, 2026.
Note 5 – Leases
Operating Lease:
The Company maintains a month-to-month lease for its research facilities at the Princeton Innovation Center BioLabs located at 303A College Road E, Princeton NJ, 08540.
Financing Lease:
The Company has financed certain laboratory equipment as follows:
| |
|
As of September 30,
|
|
| |
|
2026
|
|
|
2025
|
|
|
Cash paid for finance lease liabilities
|
|
$
|
25,617 |
|
|
$
|
52,388 |
|
Maturity of the Company’s financing lease liabilities is as follows:
|
Year ended December 31,
|
|
|
|
|
2026
|
|
$
|
8,539 |
|
|
2027 and after
|
|
|
26,725 |
|
|
Total future minimum lease payments
|
|
|
35,264 |
|
|
Less imputed interest
|
|
|
(1,746 |
)
|
|
Remaining lease liability
|
|
$
|
33,518 |
|
As of September 30, 2026, the Company had two outstanding finance leases for laboratory equipment, with remaining contractual payments extending through 2028. The leases have a discount rate of 9.15% and aggregate monthly payments of approximately $3,000. Each agreement includes a bargain purchase option to acquire the equipment at the end of the lease term.
Note 6 – Accrued Expenses
Accrued expenses consist of the following:
| |
|
As of
September 30, 2026
|
|
|
As of
December 31, 2025
|
|
Accrued research and development
|
|
$
|
669,432 |
|
|
$
|
86,100 |
|
|
Accrued professional fees
|
|
|
132,713 |
|
|
|
384,017 |
|
|
Accrued compensation
|
|
|
1,246,029 |
|
|
|
271,742 |
|
|
Accrued rent
|
|
|
370 |
|
|
|
368 |
|
|
Total
|
|
$
|
2,048,544 |
|
|
$
|
742,227 |
|
Note 7 – Stock-Based Compensation
In 2014, the Company’s stockholders approved the 2014 Equity Incentive Plan (the “Original Plan”) pursuant to which the Company may grant up to 91,367 shares as incentive stock options (“ISOs”), non-qualified stock options (“NQs”) and restricted stock units (“RSUs”), subject to increases as hereafter described (the “Plan Limit”). In addition, the Original Plan contained an evergreen provision pursuant to which, on January 1, 2015, and each January 1 thereafter and prior to the termination of the 2014 Equity Incentive Plan, pursuant to the terms of the Original Plan, the Plan Limit was and shall be increased by the lesser of (x) 4% of the number of shares of Common Stock outstanding as of the immediately preceding December 31 and (y) such lesser number as the Board of Directors may determine in its discretion. In March 2019, the Board adopted and the Company’s stockholders approved the Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the “Prior Plan”) which amended and restated the Original Plan in order to remove the evergreen provision and provide for an aggregate of 826,292 shares authorized for issuance under the Prior Plan.
On December 8, 2020, the Board adopted and on June 17, 2021, the stockholders approved, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the “Restated Plan”), which amended and restated the Prior Plan. The Restated Plan is identical to the Prior Plan in all material respects, except (a) the number of shares of Common Stock authorized for issuance under the Restated Plan was increased from 826,292 shares to 4,165,535 shares, plus the total number of shares that remained available for issuance, that were not covered by outstanding awards issued under the Prior Plan, immediately prior to December 8, 2020; and (b) the Prior Plan was amended to terminate on December 7, 2030, unless earlier terminated.
On May 19, 2023, the Board adopted, subject to stockholder approval, the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the “Third Restated Plan”). At the 2023 annual meeting of stockholders held on July 14, 2023, the stockholders approved the Third Restated Plan, which amended and restated the Restated Plan to increase the total amount of shares authorized for issuance thereunder. The Third Restated Plan is identical to the Restated Plan in all material respects, except, the number of shares of Common Stock authorized for issuance under the Third Restated Plan increased from 4,165,535 to 6,565,535.
On April 28, 2025, the Company’s Board adopted and on June 11, 2025, the stockholders approved, an amendment to the Third Restated Plan, which amendment increased the total amount of shares authorized for issuance under the Third Restated Plan to the sum of (i) 4,165,535 shares of Common Stock, which was the total number of shares of common stock authorized for issuance under the Restated Plan, plus (ii) 2,400,000 shares of common stock, which reflects the additional shares of common stock authorized by the Board under the Third Restated Plan as of its effective date, plus (iii) 3,144,049 shares of common stock that were approved at the Company’s 2025 Annual Meeting of Stockholders. As of September 30, 2026 there were 2,652,160. shares available for grant under the Third Restated Plan.
Pursuant to the terms of the Third Restated Plan, stock options have a term of ten years from the date of grant or such shorter term as may be provided in the option agreement. Unless specified otherwise in an individual option agreement, ISOs generally vest over a four-year period.
In 2018, the Company’s stockholders approved the 2018 Stock Incentive Plan pursuant to which the Company may grant up to 558,071 shares as (i) Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Preferred Stock, (v) Stock Reload Options and/or (vi) Other Stock-Based Awards. As of September 30, 2026, there were 190,799 shares available for grant under the 2018 Stock Incentive Plan.
On June 17, 2019, the Board adopted the 2019 Inducement Plan (the “Inducement Plan”). On December 8, 2020, the Company amended the Inducement Plan solely to increase the total number of shares of common stock reserved for issuance under the Inducement Plan from 200,000 shares to 500,000 shares. On May 17, 2022, the Company further amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the Inducement Plan from 500,000 shares to 1,100,000 shares. On January 22, 2024, the Company further amended the Inducement Plan solely to increase the total number of shares of Common Stock reserved for issuance under the Inducement Plan from 1,100,000 shares to 2,100,000 shares. The Inducement Plan provides for the grant of NQs. The Inducement Plan, and each amendment thereto, was recommended for approval by the Compensation Committee of the Board and subsequently approved and adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
The Inducement Plan is administered by the Compensation Committee of the Board. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, NQs under the Inducement Plan may only be granted to persons who have not previously been an employee of the Company or member of the Board of Directors of the Company (or subsidiary of the Company), and such grant is an inducement material to his or her entering into employment with the Company or its subsidiary. As of September 30, 2026, there were 1,481,897 shares available for grant under the Inducement Plan.
The following table summarizes the components of stock-based compensation expense in the Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2026 and 2025:
| |
|
Three Months Ended
September 30,
|
|
|
Nine Months ended
September 30,
|
|
| |
|
2026
|
|
|
2025
|
|
|
2026
|
|
|
2025
|
|
| |
|
(unaudited)
|
|
|
(unaudited)
|
|
|
Stock-Based Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development
|
|
$
|
257,593 |
|
|
$
|
477,592 |
|
|
$
|
982,853 |
|
|
$
|
681,654 |
|
|
General and administrative
|
|
|
582,628 |
|
|
|
768,893 |
|
|
|
2,139,917 |
|
|
|
2,266,742 |
|
|
Total
|
|
$
|
840,221 |
|
|
$
|
1,246,485 |
|
|
$
|
3,122,770 |
|
|
$
|
2,948,396 |
|
The Company granted options to purchase 2,833,162 shares during the nine month period ended September 30, 2026. The fair value of options granted during the nine months ended September 30, 2026 was estimated using the Black-Scholes option valuation model.
| |
|
Number
of Shares
|
|
|
Weighted Average
Exercise Price
|
|
Options outstanding at December 31, 2025
|
|
|
6,731,568 |
|
|
$
|
4.55 |
|
|
Granted
|
|
|
2,833,162 |
|
|
|
0.98 |
|
|
Exercised
|
|
|
- |
|
|
|
- |
|
|
Forfeited
|
|
|
(1,592,201 |
)
|
|
|
1.50 |
|
|
Expired
|
|
|
(564,296 |
)
|
|
|
5.40 |
|
|
Options outstanding at September 30, 2026
|
|
|
7,408,233 |
|
|
$
|
3.43 |
|
|
Vested and expected to vest at September30, 2026
|
|
|
7,408,233 |
|
|
$
|
3.43 |
|
|
Exercisable at September 30, 2026
|
|
|
4,175,423 |
|
|
$
|
5.50 |
|
As of September 30, 2026, the Company had approximately $4,044,498 of unamortized stock-based compensation expense, which is expected to be recognized over a remaining average vesting period of 1.15 years.
The Company granted 800,000 performance-based restricted stock units in June 2025. During the nine months ended September 30, 2026, 200,000 units were forfeited upon employee terminations, leaving 600,000 units outstanding as of September 30, 2026. All performance-based restricted stock units were unvested as of September 30, 2026 and no stock-based compensation expense was recognized, as it was not probable that the performance condition will be met under ASC 718. The fair value of performance-based restricted stock units was determined as the closing price of the Company’s common stock on the grant date.
Note 8 – Income Taxes
The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. In assessing the realizability of the net deferred tax assets, the Company considers all relevant positive and negative evidence to determine whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss carryforwards. The Company expects to have a loss for 2026 and therefore there will be no current income tax expense. The Company recorded a full valuation allowance against the net deferred tax assets as of September 30, 2026 and December 31, 2025. Consequently, the Company recorded no income tax benefit due to realization uncertainties.
The Company is subject to a U.S. federal statutory income tax rate of 21%. The primary factor impacting the effective tax rate for the three and nine months ended September 30, 2026 is the anticipated full year operating loss which will require a full valuation allowance against any associated net deferred tax assets.
Entities are required to evaluate, measure, recognize and disclose any uncertain income tax positions taken on their income tax returns. The Company has analyzed its tax positions and has concluded that as of September 30, 2026, there were no uncertain positions. The Company’s U.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the relevant year to audit by the IRS and/or state taxing authorities. The Company did not have any unrecognized tax benefits and has not accrued any interest or penalties for the three and nine months ended September 30, 2026 or for the year ended December 31, 2025.
In accordance with the State of New Jersey’s Technology Business Tax Certificate Transfer (NOL) Program, which allows certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers, the Company sold New Jersey NOL carryforwards, resulting in the recognition of $1.2 million of income tax benefit, net of transaction costs in the nine months ended September 30, 2025. There were no New Jersey NOL carryforwards sold during the nine months ended September 30, 2026 due to the Company having met the statutory $20 million lifetime cap on total cumulative value of NOLs sold, which makes the Company ineligible to participate in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss (NOL) program for 2025 and beyond.
Note 9 – Commitments and Contingencies
Rent
For month-to-month arrangements not impacted by the adoption of ASC 842, rent for the three and nine months ended September 30, 2026 was $59,227 and $182,211 respectively, compared to the three and nine months ended September 30, 2025 of $64,200 and $194,100, respectively.
Exclusive License Agreement
In December 2022, the Company entered into an exclusive global license agreement with Merck KGaA, Darmstadt, Germany (“Merck KGaA”) for the tumor targeting IL 12 fused antibody drug conjugate, M9241 (the “Merck KGaA License Agreement”). Pursuant to the Merck KGaA License Agreement, the Company agreed to make (i) development and first commercial sales milestone payments totaling up to $11 million upon the achievement of certain milestones, including the dosing of the fifth patient in a Phase 3 trial of the clinical candidate and first commercial sale of the product for a first and second indication in a major market, and (ii) up to $105 million upon achieving certain aggregate sales levels of the product.
The Company also agreed to pay Merck KGaA a royalty of 10% on aggregate net sales of product as specified in the Merck KGaA License Agreement on a product-by-product and country-by-country basis until the later of: (i) ten years after the first commercial sale of a product in a given country; and (ii) the expiration or invalidation of the licensed patents covering the compound or product in such country. The royalty rate is subject to reduction in the event that a product is not covered by a valid patent claim, a biosimilar to the compound or the product comes on the market in a particular country, or if the Company obtains a license to any intellectual property owned or controlled by a third-party which, but for such license would be infringed by making, using or selling the compound.
Option to Negotiate for an Exclusive License Agreement (Related Party)
In connection with the September 2026 Private Placement, the Company entered into an Option to Negotiate for an Exclusive License Agreement with NantWorks, an affiliate under common control with Nant Capital, LLC (a related party and accredited investor in the September 2026 Private Placement). Under ASC Topic 850, NantWorks is considered a related party. Pursuant to the agreement, the Company granted NantWorks a one-year exclusive right to negotiate an exclusive license for the PDS0101 program in exchange for and upfront, non-refundable option fee of $25,000. The agreement requires exclusive, good-faith negotiations during the applicable period, subject to its terms.
The Company is currently not a party to, and the Company’s property is not currently the subject of, any material pending legal proceedings that, if determined adversely to the
Company, would individually or taken together have a material adverse effect on the Company’s business, financial position, results of operations or cash flows. The Company may be involved, from time to time, in legal proceedings and claims
arising in the ordinary course of business. Such matters are subject to many uncertainties and outcomes that may not be predictable with assurance.
Note 10 – Venture Loan and Security Agreement
In August 2022, the Company entered into a Venture Loan and Security Agreement (the “Loan and Security Agreement”) with Horizon Technology Finance Corporation, as a lender
and collateral agent for itself and the other Lenders (in such capacity, the “Collateral Agent”), and the other persons party thereto from time to time as lenders (“Lenders”). The Company’s indebtedness under the Loan and Security Agreement was
retired and satisfied in full with a portion of the proceeds received from the Securities Purchase Agreement, as discussed in Note 11 below.
The Company recognized zero interest expense for the three and nine months ended September 30, 2026 and $0 and $1,206,035 for the three and nine months ended September 30, 2025, respectively; and zero amortization of debt discount for the three and nine months ended September 30, 2026 and $0 and $354,907, for the three and nine months ended September 30, 2025, respectively.
During the three months ended September 30, 2025, the Company recognized $1,107,005 of interest expense associated with extinguishment of debt recorded under the Loan and Security Agreement.
Note 11 – Convertible Debentures
On April 30, 2025, the Company entered into a Securities Purchase Agreement with certain third-party lenders and JGB Collateral LLC, as collateral agent (the “Securities Purchase Agreement”). Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell (i) senior secured convertible debentures (“Debentures”) in an aggregate principal amount of $22.2 million which is convertible into shares of the Company’s common stock, according to the terms, conditions, and limitations outlined in the Securities Purchase Agreement and (ii) warrants to purchase up to 1,000,000 shares of the Company’s common stock, for an exercise price of $2.52 per share (the “Warrants”), subject to adjustments as set forth in the warrants, for a total purchase price of $20.0 million.
On April 30, 2026, the Company delivered a redemption notice pursuant to which it irrevocably elected to prepay all of the outstanding principal amount under each of the Debentures, issued pursuant to that certain Securities Purchase Agreement by and among the Company, each of the buyers that are parties thereto and JGB Collateral LLC, a Delaware limited liability company, as collateral agent, dated as of April 30, 2025, for cash. On June 15, 2026, the Company paid the applicable redemption amount, equal to 103% of the principal amount outstanding plus all accrued and unpaid interest and all other amounts payable thereunder, and, upon such payment, each Debenture was redeemed in full and is of no further force or effect.
For the three and nine months ended September 30, 2026, the Company recognized interest expense of $0 and $1,636,779, respectively. For the three and nine months ended September 30, 2026 the Company amortized $0 and $714,386 of the debt discount, and as of September 30, 2026, had a remaining debt discount balance of $0.
For the three and nine months ended September 30, 2025, the Company recognized interest expense of $1,148,365 and $1,905,622, respectively. For the three and nine months ended September 30, 2025, the Company amortized $445,658 and $724,520, respectively, of the debt discount, and as of September 30, 2025, had a remaining debt discount balance of $3,332,908.
During the three months ended September 30, 2026, the Company recognized $0 of interest expense associated with extinguishment of debt recorded under the Debentures.
Note 12 – Promissory Note
On June 15, 2026, the Company issued a promissory note to YA II PN, Ltd. with an aggregate principal amount of $6,000,000 (the “Promissory Note”) and a warrant to purchase up to 2,158,274 shares of common stock of the Company, par value $0.00033 per share, at an exercise price of $1.1824 per share, subject to adjustments, for gross proceeds of $5.76 million. The promissory note bore interest at 10% per annum and had a stated maturity of June 15, 2027.
On September 14, 2026, the Company repaid in full the promissory note issued to YA II PN, Ltd. on June 15, 2026, as amended on August 31, 2026, by paying approximately $4.6 million, consisting of all remaining outstanding principal and accrued and unpaid interest. No early termination penalties were incurred in connection with the repayment. Upon repayment, the promissory note was terminated, and no amounts remain outstanding as of September 30, 2026.
For the three and nine months ended September 30, 2026, the Company recognized interest expense of $660,236 and $686,903, respectively. For the three and nine months ended September 30, 2026 the Company amortized $1,652,917 and $1,652,917 respectively, of the debt discount, and as of September 30, 2026, had a remaining debt discount balance of $0.
During the three months ended September 30, 2026, the Company recognized $1,105,331 of interest expense associated with extinguishment of debt recorded under the Promissory Note.
Note 13 – Retirement Plan
The Company has a 401(k) defined contribution plan for the benefit of all employees and permits voluntary contributions by employees, subject to IRS-imposed limitations, which are matched by the Company. The 401(k) employer contributions were $38,041 and $141,984 for the three and nine months ended September 30, 2026, respectively, compared to the three and nine months ended September 30, 2025 of $47,145 and $163,978, respectively.
Note 14 – Segment Reporting
In accordance with FASB ASC Topic 280, Segment Reporting, the Company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy. The financial results of the Company’s operations are managed and reported to the Chief Executive Officer who is considered the Company’s chief operating decision maker (CODM), on a consolidated basis.
The CODM assesses performance and allocates resources based on the Company’s consolidated statements of operations and key components and processes of the Company’s operations are managed
centrally. Segment asset information is not used by the CODM to allocate resources.
As a single reportable segment entity, the Company’s segment performance measure is net income / (loss) attributable to stockholders. Significant segment expenses, as provided to the CODM, are presented below:
| |
|
Three Months Ended September 30,
|
|
|
Nine Months Ended September 30,
|
|
| |
|
2026
|
|
|
2025
|
|
|
2026
|
|
|
2025
|
|
|
Segment expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Salaries and Benefits
|
|
$
|
3,073,867 |
|
|
$
|
3,656,376 |
|
|
$
|
9,849,750 |
|
|
$
|
10,343,215 |
|
|
Professional fees
|
|
|
1,789,137 |
|
|
|
1,465,862 |
|
|
|
3,807,296 |
|
|
|
3,871,489 |
|
|
General administrative expenses
|
|
|
319,481 |
|
|
|
361,546 |
|
|
|
971,351 |
|
|
|
1,093,797 |
|
|
Clinical development expenses
|
|
|
376,360 |
|
|
|
1,898,406 |
|
|
|
2,730,262 |
|
|
|
3,213,001 |
|
|
Other development expenses
|
|
|
337,259 |
|
|
|
757,952 |
|
|
|
1,555,267 |
|
|
|
6,347,749 |
|
|
Total operating and segment expenses
|
|
$
|
5,896,104 |
|
|
$
|
8,140,142 |
|
|
$
|
18,913,926 |
|
|
$
|
24,869,251 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
41,630 |
|
|
|
281,109 |
|
|
|
353,850 |
|
|
|
992,582 |
|
|
Interest expense
|
|
|
(1,766,451 |
)
|
|
|
(1,150,378 |
)
|
|
|
(6,160,480 |
)
|
|
|
(4,225,737 |
)
|
|
Benefit from income taxes
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,169,820 |
|
|
Segment and consolidated net loss
|
|
$
|
(7,620,925 |
)
|
|
$
|
(9,009,411 |
)
|
|
$
|
(24,720,556 |
)
|
|
$
|
(26,932,586 |
)
|
Note 15 – Subsequent Events
On October 14, 2026, the Company filed a registration statement on Form S-3 covering the resale of shares of common stock issued or issuable in connection with the September 2026
Private Placement, including shares issuable upon the exercise of the September Pre-Funded Warrants and September Common Warrants. The Company will not receive any proceeds from sales by the selling stockholders but may receive proceeds from any
cash exercise of the September Pre-Funded Warrants and September Common Warrants.
On October 18, 2026, Kamil Ali-Jackson, Stephen Glover, Gregory Freitag and Otis Brawley resigned from the Board of Directors, and the Board of Directors appointed Deborah A. Ramsdell, John A. Dawson CBE and Bruce Wendel as directors and fixed the size of the Board at seven directors.
On November 9, 2026, NantWorks exercised all of its outstanding common stock warrants issued in connection with the Company’s September 2026 private placement. The warrants covered 17,699,115 shares of common stock and had an exercise price of $0.22 per share. The Company received approximately $3.9 million in gross proceeds from the exercise. Under the terms of the warrants, the Company issued pre-funded warrants in lieu of common shares for the portion of the exercise that would have caused the holder to exceed the 19.9% beneficial ownership limitation. The pre-funded warrants have an exercise price of $0.00033 per share, have no expiration date and are subject to the same beneficial ownership limitation.
| ITEM 2. |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited interim
condensed consolidated financial statements and related notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q (this “Quarterly
Report”) and with the audited financial statements and notes thereto of the Company as of and for the year ended December 31, 2025 on Form 10-K, filed with the Securities and Exchange Commission, or SEC, on March 30, 2026, as amended by Amendment No. 1 on Form 10-K/A filed April 28, 2026.
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section
27A of the United States Securities Act of 1933, as amended) concerning the Company and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition,
or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend
upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar
expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained
in any forward-looking statement as a result of various factors, including, without limitation:
|
● |
the Company’s recent strategic refocus to prioritize the development of PDS0301 and to discontinue the VERSATILE-003 Phase 3 clinical trial of PDS0101 may not achieve the anticipated benefits and involves
significant risks and uncertainties;
|
|
● |
the Company’s ability to protect its intellectual rights;
|
|
● |
the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings;
|
|
● |
the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its clinical and product candidates, and the risks that raising such additional
capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or clinical and product candidates;
|
|
● |
the Company’s limited operating history in the current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful
implementation of such business plan;
|
|
● |
the timing for the Company or its partners to initiate the planned clinical trials for PDS0301 (formerly PDS01ADC);
|
|
● |
the Company’s ability to successfully secure partnership(s) for the further development of its PDS0101 program;
|
|
● |
the Company may not be able to identify, negotiate, or consummate strategic partnerships or other externally funded opportunities for the continued development of PDS0101, and any such partnerships may not be
on favorable terms;
|
|
● |
the Company may expend its limited resources to pursue PDS0301 and fail to capitalize on other product candidates or indications that may be more profitable or for which there is a greater likelihood of
success;
|
|
● |
the discontinuation of the VERSATILE-003 Phase 3 trial and the Company’s limited cash resources may further impact the Company’s ability to continue as a going concern;
|
|
● |
the successful implementation of the Company’s research and development programs and collaborations, including any collaboration trials concerning the Company’s PDS0301, Versamune® and Infectimune® based
clinical and product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s clinical and product
candidates;
|
|
● |
the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current clinical candidates, including statements regarding the timing of initiation,
pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and
data reported in an abstract, and receipt of interim results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials;
|
|
● |
expectations for the clinical and preclinical development, manufacturing, regulatory approval, and commercialization of the Company’s clinical and product candidates;
|
|
● |
any Company statements about its understanding of clinical and product candidates’ mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and
any collaboration trials; the acceptance by the market of the Company’s clinical and product candidates, if approved;
|
|
● |
the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Company’s clinical and product
candidates; and
|
|
● |
other factors, including legislative, regulatory, political and economic developments not within the Company’s control, including unforeseen circumstances or other disruptions to normal business operations
arising from or related to those listed under Part II, Item 1A. Risk Factors.
|
Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these
forward-looking statements for any reason, whether as a result of new information, future events or otherwise.
In this Quarterly Report, unless otherwise stated or the context otherwise indicates, references to “PDS Biotech,” “the Company,” “we,” “us,” “our” and similar references refer to
PDS Biotechnology Corporation, a Delaware corporation, and subsidiary.
Company Overview
We are a clinical-stage biotechnology company focused on developing PDS0301, a tumor-targeted IL-12 immunocytokine designed to modify the tumor microenvironment and enhance the
activity and durability of anti-cancer therapies. Our current development strategy prioritizes PDS0301, including its development in colorectal cancer and evaluation in other indications.
We also develop our proprietary Versamune® platform for treatments in oncology and Infectimune® for treatments in infectious diseases. Our most advanced Versamune® drug candidate,
PDS0101, was evaluated in multiple clinical trials and we seek to further the development of PDS0101 through strategic partnerships.
We believe our investigational targeted immunotherapies have the potential to overcome the limitations of current immunotherapy approaches through the activation of the right
type, quantity and potency of T cells. PDS0301, Versamune®, and Versamune® in combination with PDS0301 are being developed for treatments in oncology and Infectimune® is being developed for the prevention of infectious diseases. PDS0301 is an
investigational tumor targeting IL-12 that we believe may enhance the proliferation, potency and longevity of T cells in the tumor microenvironment.
In March 2025, we announced the initiation of our VERSATILE-003 Phase 3 clinical trial evaluating PDS0101 in HPV16-positive first-line treatment of recurrent/metastatic head and neck squamous cell
carcinoma.
In July 2025, we announced that the colorectal cancer cohort of a Phase 2 clinical trial with PDS0301 in combination with Hepatic Artery Infusion Pump (HAIP) and systemic therapy met the
pre-defined criteria for expansion to stage 2 following positive stage 1 results.
In August 2025, we announced final topline survival data from our VERSATILE-002 Phase 2 trial in head and neck cancer.
In October 2025, we announced our intent to seek expedited approval pathway for PDS0101 in HPV16-positive head and neck cancer based on final VERSATILE-002 trial data showing robust median
progression free survival and increased median overall survival of the patients.
In December 2025, we announced the occurrence of a type C meeting with the FDA to discuss a proposed accelerated approval pathway for PDS0101 in HPV16-positive recurrent
and/or metastatic head and neck cancer.
In February 2026, we announced the adoption of an amended protocol for our VERSATILE-003 Phase 3 trial incorporating progression free survival (PFS) as a primary endpoint for interim analysis and
potential accelerated approval.
In August 2026, we announced a strategic refocus to prioritize PDS0301, our tumor-targeted IL-12 immunocytokine, as our lead development program. As part of this strategic update, we announced our
plan to cease further internal investments in PDS0101, including the discontinuation of the VERSATILE-003 Phase 3 trial, and our intention to pursue strategic partnerships or other externally funded opportunities for the continued development of
PDS0101.
On September 14, 2026, we completed the initial closing of the September 2026 Private Placement, raising approximately $11.3 million in gross proceeds through the issuance of common stock,
pre-funded warrants and accompanying common stock purchase warrants. The transaction also provides for a contingent milestone closing involving an additional $11 million, subject to submission of the specified PDS0301 Phase 3 protocol and
satisfaction or waiver of applicable closing conditions. We repaid the Promissory Note in full on September 14, 2026 for approximately $4.6 million, including accrued interest. See Notes 3, 9 and 12 to the condensed consolidated financial
statements.
Clinical Candidate Pipeline
IL-12 Oncology Immunocytokine Pipeline
PDS0301 is a novel investigational IL-12 fused antibody drug conjugate (IgG1), tumor-targeting interleukin 12 (IL-12) immune-cytokine that enhances the proliferation, potency
and longevity of T cells in the tumor microenvironment. Together with Versamune® based immunotherapies PDS0301 works synergistically to overcome tumor immune suppression and to promote a targeted T cell attack against cancers. As with Versamune®,
PDS0301 is given by a simple subcutaneous injection. Clinical data suggests the addition of PDS0301 to Versamune® based immunotherapies may demonstrate significant disease control in advanced cancer patients by shrinking tumors and/or prolonging
life.
PDS0301 has been designed to overcome the limitations of cytokine therapy as explained above, and based on extensive preclinical studies performed at the NCI evaluating PDS0301 as a monotherapy
and also in combinations with established standard of care treatments for cancer, we believe that PDS0301 has significant potential as a cytokine therapy. Based on the informative preclinical studies, a number of ITT Phase 2 trials are currently
in progress at the NCI, some of which are outlined below:
|
● |
A Phase 2 trial evaluating PDS0301 in combination with hepatic artery infusion pump (HAIP) and systemic therapy for subjects with metastatic colorectal cancer, intrahepatic cholangiocarcinoma, or metastatic adrenocortical carcinoma (in
progress)
|
|
● |
A Phase 2 trial evaluating ICI naïve and resistant patients with HPV-positive malignancies treated with PDS0301, PDS0101 and bintrafusp alfa (completed and published in JAMA Oncology 2025)
|
|
● |
A Phase 2 trial evaluating T-cell clonality after stereotactic body radiation therapy alone and in combination with the immunocytokine PDS0301 in localized high and intermediate risk prostate cancer treated with androgen deprivation
therapy (in progress)
|
|
● |
A Phase 1/2 trial evaluating PDS0301 in combination with enzalutamide vs enzalutamide in adults with biochemically recurrent prostate cancer (in progress)
|
|
● |
A Phase 1/2 trial evaluating PDS0301 in combination with docetaxel in adults with metastatic castration sensitive and castration resistant prostate cancer (in progress)
|
|
● |
A Phase 1/2 trial evaluating PDS0301 going forward as a monotherapy in advanced kaposi sarcoma (in progress)
|
|
● |
A Phase 1/2 trial evaluating PDS0301 in combination with a histone deacetylase (HDAC) inhibitor in ICI-resistant MUC1-positive colon and bladder cancers among others
|
In October 2023, interim safety and immune response data was presented for the first-in-human Phase1/2 clinical trial evaluating PDS0301 in combination with current SOC chemotherapy, docetaxel,
to treat metastatic castration sensitive and castration resistant prostate cancer. The data was featured in an oral presentation at the 11th Annual Meeting of the International Cytokine & Interferon Society. The data presented
included the following:
|
● |
Decrease in PSA levels was seen in all patients at all three tested doses of PDS0301 and 61% of patients had at least a 60% decrease in PSA levels.
|
|
● |
All doses of the combination were well-tolerated with one patient experiencing Grade 4 neutropenia.
|
|
● |
Administration of the combination was associated with decreases in T reg cells and increases in activated natural killer (NK) cells, memory CD8 T cells, proliferating CD4 and CD8 T cells and cytokines INF-γ and Interleukin 10 (IL-10).
|
|
● |
The changes in immune responses with the combination were independent of the PDS0301 dose.
|
In April 2026, we announced the publication of clinical and immunological biomarker data from Stage 1 of a Phase 2 trial evaluating PDS0301 in patients with advanced colorectal cancer with liver
metastases in the March 10, 2026 issue of Journal of Clinical Oncology (JCO) Oncology Advances. Key findings from stage 1 of the Phase 2 trial are outlined below:
|
● |
Objective response rate by RECIST v1.1: 77.8% (7/9) at six months; in the parallel trial without PDS0301, the ORR was 35% (7/20)
|
|
● |
24-month survival rate: Approximately 80%; in the parallel study without PDS0301, the 2-year survival rate was approximately 40%
|
|
● |
Extrahepatic progression-free survival (PFS): median not reached at minimum follow-up of 13.1 months; in the parallel trial without PDS0301, the PFS was 8.1 months
|
We are working closely with the NCI to determine the best pathway forward for the prioritized PDS0301 studies. In January 2025, we submitted an investigational new
drug application to the FDA for a Phase 1 trial with PDS0301 and PDS0103 in colorectal cancer. At the time of this Quarterly Report, we have not initiated this trial.
VERSATILE-003: PDS0101 + pembrolizumab vs pembrolizumab
In March 2025, we initiated our VERSATILE-003 Phase 3 clinical trial evaluating the combination of PDS0101 in combination with the anti-PD-1 therapy pembrolizumab versus pembrolizumab as a
monotherapy. The clinical trial was designed to evaluate the efficacy and safety of this therapeutic combination as a first line treatment in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16)
infection.
In this trial, sponsored by us, patients whose cancer has returned following initial treatment or spread (metastasized) were treated with either the combination of PDS0101 and pembrolizumab or with
pembrolizumab alone, to evaluate if the addition of PDS0101 might improve the efficacy of pembrolizumab alone. Patients in the trial received a total of 5 cycles of combination therapy in the context of standard of care pembrolizumab therapy
administered every three weeks until disease progression. The primary endpoint of VERSATILE-003 was median overall survival, (mOS). The trial was paused as we proposed regulatory modifications to the trial protocol that would potentially allow for
an accelerated approval. Following discussions with the FDA in December 2025, we amended the trial’s protocol, among other modifications, to include progression-free survival (PFS) as an interim primary endpoint of the trial. Patients already
enrolled prior to the amendment remain on the trial and continue to receive treatment.
In August 2026, we announced the discontinuation of the trial, and the decision to seek a commercialization partner to sponsor or co-sponsor the trial.
VERSATILE-002: PDS0101 + Keytruda®
In November 2020, we commenced our VERSATILE-002 Phase 2 clinical trial evaluating the combination of PDS0101 in combination with Merck’s anti-PD-1 therapy, Keytruda® (pembrolizumab) which is the
FDA-approved standard of care for first-line treatment of recurrent/ metastatic head and neck cancer. Enrollment in stage 2 of 2 for the ICI-naïve arm and the ICI-resistant arms are complete. The clinical trial evaluated the efficacy and safety
of this therapeutic combination as a first and second line treatment in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection.
In this trial sponsored by us, patients whose cancer had returned following initial treatment or spread were treated with the combination of PDS0101 and Keytruda®
to evaluate if the addition of PDS0101 might improve the efficacy reported in published studies of Keytruda® alone. Patients in the trial received a total of 5 cycles of combination therapy in the context
of standard of care Keytruda® therapy administered every three weeks until disease progression. The primary endpoint of VERSATILE-002 was the objective response rate, or ORR, at six months following
initiation of treatment. There were two cohorts in the trial. Cohort 1 was for patients who have yet to be treated with an immune checkpoint inhibitor (ICI naïve) and cohort 2 which consisted of patients
who had failed immune checkpoint inhibitor therapy (ICI resistant).
In May 2023, we completed enrollment in the ICI naïve arm. We filed our amended IND with the FDA in the third quarter of 2023. In October 2023, we received feedback from the FDA
on the amended IND.
In June 2023, an abstract was presented at the 2023 American Society of Clinical Oncology: Abstract number 6012, Safety and Efficacy of Immune Checkpoint
Inhibitor (ICI) Naïve Cohort from Study of PDS0101 and Pembrolizumab in HPV16-positive Head and Neck Squamous Cell Carcinoma (HNSCC). The abstract was also selected as one of the featured posters to be reviewed by an expert panel in the Head and
Neck Cancer discussion session. Data on 34 patients was presented. The data from the abstract is as follows:
|
● |
Estimated 12-month overall survival rate was 87.1%. Published results are 36-50% with approved ICIs used alone.
|
|
● |
Median progression-free survival was 10.4 months (95% CI 4.2, 15.3). Published results are median PFS of 2-3 months for approved ICIs when used as monotherapy in patients with similar PD-L1 levels.
|
|
● |
A disease control rate (disease stabilization or tumor shrinkage) of 70.6% (24/34)
|
|
● |
Confirmed and unconfirmed objective response rate is 41.2% (14/34 patients), which is identical to the preliminary response rate data previously reported by us at ASCO 2022 (7/17 patients). To date these responses have been confirmed in
nine of the 34 patients (26.5%), including one complete response.
|
|
● |
15/34 patients (44.1%) had stable disease.
|
|
● |
9/34 patients (26.5%) had progressive disease.
|
|
● |
4/48 (8.3%) of patients had a Grade 3 treatment-related adverse event (TRAE). No Grade 4 or higher TRAEs were observed.
|
In October 2023, at a key opinion roundtable updated interim data was presented based on an August 2, 2023 cut-off from our VERSATILE-002 Phase 2 clinical trial evaluating the combination of
PDS0101 in combination with Merck’s anti-PD-1 therapy, Keytruda® (pembrolizumab) which is an FDA-approved standard of care for first-line treatment of recurrent/ metastatic head and neck cancer. Data on 52 patients was presented. The data from the
roundtable based on investigator assessment was as follows:
Highlights from the ICI naïve cohort include:
|
● |
24-month overall survival (OS) rate is 74%; published 24-month survival rate of less than 30% for approved ICI.
|
|
● |
12-month OS rate is 80%; published results of 30-50% with approved ICIs.
|
|
● |
Tumor shrinkage seen in 60% (31/52) of patients.
|
|
● |
Confirmed overall response rate ORR is 27% (14/52) to date.
|
|
● |
Median progression-free survival (PFS) is 8.1 months to date; published results of 2-3 months PFS with approved ICIs.
|
|
● |
13% (8/62) of patients experienced Grade 3 treatment-related adverse events (TRAE) and 0% (0/62) experienced Grade 4 or 5 TRAE; published results report 13-17% Grade 3-5 TRAE with approved ICI monotherapy.
|
|
● |
60% (33/55) of patients have CPS score of 1-19 (who generally have a weaker response to Keytruda®), and 40% (22/55) have CPS score >20 (who generally have a higher response to Keytruda®).
|
Highlights from the ICI refractory cohort include:
|
● |
The 12-month OS rate is 56%. The published median 12-month OS rate is 17% with no salvage chemotherapy following tumor progression on ICI (ICI Resistant).
|
|
● |
0% (0/21) confirmed ORR suggests that PDS0101’s impact on survival does not appear to be dependent on tumor shrinkage.
|
|
● |
4% (1/25) of patients experienced Grade 3 TRAE and 0% (0/21) patients experienced Grade 4 and 5 TRAE.
|
In May 2024, at a virtual key opinion leader event, updated interim data was presented based on a November 30, 2023 cut-off from our VERSATILE-002 Phase 2 clinical trial evaluating the combination
of PDS0101 in combination with Merck’s anti-PD-1 therapy, Keytruda® (pembrolizumab) which is an FDA-approved standard of care for first-line treatment of recurrent/metastatic head and neck cancer. Data from 53 patients was presented. The data from
the event based on investigator assessment was as follows:
Highlights from the ICI naïve cohort with CPS > 1 included:
|
● |
Median overall survival of 30 months; published results for ICIs are 7-18 months.
|
|
● |
Confirmed overall response rate ORR of 34% (18/53) to date; published results for comparable patients receiving treatment with ICIs are less than 20%.
|
|
● |
Confirmed complete responses, partial responses and stable disease according to RECIST v1.1 were seen in 75.5% of patients.
|
|
● |
Median progression-free survival (PFS) of 6.3 months to date; published results of 2-3 months PFS with approved ICIs.
|
|
● |
The combination of PDS0101 and Keytruda® appeared to be well tolerated with 11% (7/62) of patients experienced Grade 3 treatment-related adverse events (TRAE) and 2% (1/62) experienced Grade 4 or 5 TRAE; published results report 13-17%
Grade 3-5 TRAE with approved ICI monotherapy.
|
|
● |
60% (32/53) of patients had CPS score of 1-19 (who generally have a weaker response to Keytruda®), and 40% (21/53) have CPS score >20 (who generally have a higher response to Keytruda®).
|
In June 2024, we provided a data update from our VERSATILE-002 clinical trial. Interim data was presented based on a May 17, 2024 cut-off. The data update was as follows:
|
● |
Median Overall Survival of 30 months, consistent with data presented our key opinion leader event in May of 2024, which was based on a data cut as of November 30, 2023.
|
|
● |
27 of the censored patients remained alive and were awaiting their next clinical assessment, 6 censored patients had withdrawn consent for further follow-up, and 2 patients had been lost to follow-up, and 18 patients had died.
|
|
● |
The lower limit of the 95% confidence interval is 19.7 months, and the upper limit is not yet estimable, as the majority of patients continue to be followed for survival.
|
In August 2024, we provided an update to our clinical strategy following discussions with the FDA. During the August 2024 update, we announced our intent to initiate a registrational trial in
first line treatment in HPV16-positive recurrent/metastatic HNSCC with the double combination of PDS0101 + pembrolizumab.
In September 2024, we announced updated data from our VERSATILE-002 Phase 2 clinical trial presented during a poster session at the European Society for Medical Oncology (ESMO) Congress 2024.
The data presented was based on a May 17, 2024 data cut-off. The main elements of the update were as follows:
|
● |
Median Overall Survival (mOS) was 30 months with a lower 95% confidence interval of 19.7 months; Published mOS for pembrolizumab is 12-18 months
|
|
● |
Objective Response Rate (ORR) of 36% (19/53); Published ORR for pembrolizumab is 19-25%
|
|
● |
Disease Control Rate (DCR) is 77% (41/53)
|
|
● |
21% (11/53) of patients had deep tumor responses and shrinkage of 90-100%
|
|
● |
9% (5/53) of patients had a complete response
|
|
● |
Treatment-related adverse events of Grade ≥3 were seen in 9 patients (Grade 3, n=8 and Grade 4, n=1)
|
In August 2025, we announced final topline survival data from our VERSATILE-002 Phase 2 trial in head and neck cancer.
53 patients were enrolled in the 1L R/M HNSCC arm of the trial:
|
● |
The median overall survival (mOS) is 39.3 months in patients with CPS ≥ 1. The lower limit of the 95% confidence interval is 23.9 months, and the upper limit is not yet estimable.
|
MD Anderson Cancer Center (IMMUNOCERV): PDS0101 + Chemoradiotherapy
In October 2020, a Phase 2 IIT was initiated with The University of Texas MD Anderson Cancer Center. This clinical trial investigated the safety and anti-tumor efficacy of PDS0101
in combination with standard-of-care chemo-radiotherapy, or CRT, and their correlation with critical immunological biomarkers in patients with locally advanced cervical cancer. We believe that Versamune® has strong T cell induction with the
potential to enhance efficacy of the current standard of care CRT treatment in this indication.
In November 2022, data from this trial was included in a poster presentation at the 2022 SITC Annual Meeting which included the following:
|
● |
9 of the 17 patients had completed a Day 170 post-treatment positron emission tomography, computed tomography (PET CT) scan to assess the status of the cancer. This included 78% (7/9) of treated patients with
advanced cervical cancer (FIGO stage III or IV).
|
|
● |
100% (9/9) of patients treated with the combination of PDS0101 and CRT had an objective response.
|
|
● |
89% (8/9) of patients treated with the combination of PDS0101 and CRT demonstrated a complete response (CR) on Day 170 by PET CT. One patient who received 3 of the 5 scheduled doses of PDS0101 showed signs of
residual disease. One patient who had a CR died from an event unrelated to either their underlying disease or treatment.
|
|
● |
1-year disease-free survival and 1-year overall survival of 89% (8/9) in patients treated with the combination of PDS0101 and CRT.
|
|
● |
As previously reported, data confirmed PDS0101 treatment activates HPV16-specific CD8 T cells. This increase was not seen in patients who did not receive PDS0101. The increase in HPV16-specific T cells
generated by the treatment is positively correlated with tumor cell death, suggesting cytotoxic CD8 T cells are important mediators of antigen-specific immunity.
|
|
● |
The data affirms that PDS0101 activates Type 1 interferon pathway in humans, mimicking the mechanism previously demonstrated in preclinical studies in animal models.
|
|
● |
Toxicity of PDS0101 remains limited to low-grade local injection site reactions.
|
In October 2023, data was reported demonstrating that PDS0101 in combination with standard-of-care (SOC) chemoradiotherapy was associated with a rapid decline in human papillomavirus circulating
cell-free DNA (ctHPV-DNA), a potential predictive biomarker of treatment response and patient survival. The data from the IMMUNOCERV Phase 2 clinical trial was featured in an oral presentation at the American Society for Radiation Oncology Annual
Meeting which included the following:
|
● |
Earlier and greater proportion of ctDNA clearance with PDS0101 plus chemoradiation (CRT) vs. SOC CRT alone 81.3% clearance after 3 weeks vs. 30.3% with SOC (p=0.0018), and 91.7% of clearance at 5 weeks vs. 53.1% with SOC (p=0.0179).
|
|
● |
Baseline ctDNA levels correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage and lymph node involvement; 100% of patients treated with PDS0101 had cancer that had spread to the lymph nodes.
|
In October 2024, we announced updated data from the IMMUNOCERV Phase 2 clinical trial evaluating PDS0101 with chemoradiation to treat locally advanced cervical cancer presented at the American
Society for Radiation Oncology (ASTRO) Annual Meeting 2024 which included the following:
|
● |
All patients received at least 2 doses of PDS0101.
|
|
● |
Median follow-up was 19 months.
|
|
● |
36-month overall survival (OS) rate was 84.4% among all patients, and 100% for the eight patients who received all five doses of PDS0101. Historical published data show 36-month OS rate with chemoradiation in
this population of approximately 64%.
|
|
● |
36-month progression free survival (PFS) rate was 74.9% among all patients and 100% for the eight patients who received all five doses of PDS0101. Historical published data show 36-month PFS rate with
chemoradiation in this population of approximately 61%.
|
|
● |
Complete metabolic response (CMR) was achieved in 15/17 (88%) patients.
|
|
● |
PDS0101 appeared to be safe and well-tolerated. The most common treatment-related toxicities were injection site reactions in 12/17 (71%) patients.
|
Mayo Clinic: PDS0101 Monotherapy and in combination with pembrolizumab
In February 2022, we initiated an Investigator-Initiated Trial (ITT), MC200710, for PDS0101 alone or in combination with the immune checkpoint inhibitor, pembrolizumab, in patients
with HPV-positive oropharyngeal cancer (HPV(+)OPSCC) at high risk of recurrence. The trial was led by Drs. David Routman, Katharine Price, Kathryn Van Abel, and Ashish Chintakuntlawar at Mayo Clinic, a nationally and internationally recognized
center of excellence for the treatment of head and neck cancers.
In this trial, treatment was administered before patients proceeded to transoral robotic surgery (TORS) with curative intent, or received chemotherapy. Treatment in this setting is
referred to as neoadjuvant treatment. PDS0101 has been shown to induce killer T cells that target and kill HPV-positive cancers, either alone or in combination with ICIs in preclinical studies, and in combination in clinical studies of patients
with advanced recurrent/metastatic HPV-positive cancers. This trial explored whether PDS0101 with or without checkpoint inhibition may increase HPV-specific anti-tumor responses, potentially resulting in tumor shrinkage, pathologic regression, and
decreases in circulating tumor DNA (ctDNA). This study was a window of opportunity study and patients only received two doses of therapy.
National Cancer Institute: PDS0101 + PDS0301 + Bintrafusp Alfa
In November 2023, we released updated interim survival data as follows:
|
● |
75% of immune checkpoint inhibitor (ICI) naïve patients remain alive at 36 months; published median overall survival (OS) in similar patients is 7-11 months
|
|
● |
12-month survival rate in (ICI) resistant patients of 72%
|
|
● |
Median OS in ICI-resistant HPV-positive patients is approximately 20 months; published median OS is 3.4 months
|
In April 2020, an existing Cooperative Research and Development Agreement (“CRADA”) between PDS Biotech and the NCI was expanded beyond PDS0101 to include clinical and preclinical development of
PDS0103. PDS0103 is an investigational immune therapy owned by us and designed to treat cancers associated with the mucin-1, or MUC1, oncogenic protein. These include cancers such as ovarian, breast, colorectal and lung cancers. PDS0103 combines
Versamune® with novel highly immunogenic agonist epitopes of MUC1 developed by the NCI and licensed by us.
MUC1 is highly expressed in several types of cancer and has been shown to be associated with drug resistance and poor disease prognosis in breast, colorectal, lung and ovarian cancers, for which
PDS0103 is being developed. Expression of MUC1 is often associated with poor disease prognosis, due in part to drug resistance. In preclinical studies, and similarly to PDS0101, PDS0103 demonstrated the ability to generate powerful MUC1-specific
CD8 killer T cells.
In January 2025, we submitted an investigational new drug application to the FDA for a Phase 1 trial with PDS0301 and PDS0103 in MUC1 positive cancers. At the time of this Quarterly
Report, we have not initiated this trial.
Infectimune® Development Strategy
We believe that the key differentiating attributes of the Infectimune® platform technology are strong induction of CD8 and CD4 T cells as well as antibodies which can be leveraged
to improve treatment and preventive options in several infectious disease indications. In January 2022, we presented preclinical data on our universal flu program sponsored by the National Institute of Allergy and Infectious Disease (NIAID)
demonstrating the potential of the Infectimune® technology with computationally designed influenza proteins developed by the laboratory of Dr. Ted Ross at the University of Georgia to generate broadly protective anti-influenza immune responses
across multiple strains of influenza. This data has provided a unique opportunity to highlight the potentially transformative utility of Infectimune® in the development of more broadly effective and longer lasting protective vaccines. Current
preventive and prophylactic vaccine approaches and technologies predominantly focus on creating strong induction of antibody responses. However, the induction of T cell responses, in addition to antibody responses, provides more durable and broad
protection against infectious diseases.
Based on the preclinical data with the universal seasonal flu vaccine and the current focus of the NIAID in developing more effective flu vaccines, we have decided to focus our
near-term infectious disease activities to align with the interests of the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs) program. This will involve development of a universal seasonal flu vaccine and the potential development of
a universal pandemic influenza vaccine based on similar computationally designed antigens as have shown promise with Infectimune®.
Clinical Development Strategy
Since our inception we have devoted substantially all our resources to developing our Versamune® and Infectimune® platforms, and products derived thereof, as well as PDS0301. This
includes advancing preclinical programs, conducting clinical trials, manufacturing PDS0101 and PDS0301 for clinical trials, and providing general and administrative support. We have funded our operations primarily from the issuance of common stock
and issuance of debt. We have not generated any product revenue to date.
We have never been profitable and have incurred net losses in each year since inception. Our net losses were $24.7 million, and $26.9 million
for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, we had an accumulated deficit of $241.3 million. Substantially all of our net losses have resulted from costs incurred in connection with our research
and development programs and from general and administrative costs associated with these operations.
As of September 30, 2026, we had $15.2 million in cash and cash equivalents.
Our future funding requirements will depend on many factors, including the following:
|
● |
the timing and costs of our planned and ongoing clinical trials;
|
|
● |
the outcome, timing and costs of seeking regulatory approvals;
|
|
● |
the terms and timing of any future collaborations, licensing, consulting or other arrangements that we may enter into;
|
|
● |
the amount and timing of any payments we may be required to make in connection with the licensing, filing, prosecution, maintenance, defense and enforcement of any patents or patent applications or other
intellectual property rights; and
|
|
● |
the extent to which we license or acquire other products and technologies.
|
SELECTED FINANCIAL OPERATIONS OVERVIEW
Revenue
We have not generated any revenues from commercial product sales and do not expect to generate any such revenue in the near future. We may generate revenue in the future from a
combination of research and development payments, license fees and other upfront payments or milestone payments.
Research and Development Expenses
Research and development expenses include employee-related expenses, costs to acquire license rights to use certain technology in our research and development projects, costs of
acquiring, developing and manufacturing clinical trial materials, as well as fees paid to consultants and various entities that perform certain research and testing on our behalf. Costs for certain development activities, such as clinical trials,
are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided by vendors on their actual costs incurred. Payments for these activities
are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the Condensed Consolidated Financial Statements as prepaid or accrued expenses. Costs incurred in connection with
research and development activities are expensed as incurred.
We expect that our research and development expenses will increase significantly over the next several years as we advance our PDS0301 product candidate into and through
clinical trials, pursue regulatory approval of our Versamune® and PDS0301 product candidates and prepare for a possible commercial launch, all of which will also require a significant investment in contract research services, manufacturing
process validation and inventory related costs.
The process of conducting human clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving marketing approval for our
clinical and product candidates. The probability of successful commercialization of our clinical and product candidates may be affected by numerous factors, including clinical data obtained in future trials, competition, manufacturing capability
and commercial viability. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our
clinical and product candidates.
Results of Operations
Comparison of the Three months September 30, 2026 and 2025
The following table summarizes the results of our operations for the three months ended September 30, 2026 and 2025:
| |
|
Three Months Ended
September 30,
|
|
|
Increase ( Decrease)
|
|
| |
|
2026
|
|
|
2025
|
|
|
$ Amount
|
|
|
%
|
|
| |
|
(in thousands)
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses
|
|
$
|
2,051
|
|
|
$
|
4,576
|
|
|
$
|
(2,525
|
)
|
|
|
(55
|
)%
|
|
General and administrative expenses
|
|
|
3,845
|
|
|
|
3,564
|
|
|
|
281
|
|
|
|
8
|
%
|
|
Total operating expenses
|
|
|
5,896
|
|
|
|
8,140
|
|
|
|
(2,244
|
)
|
|
|
(28
|
)%
|
|
Loss from operations
|
|
|
(5,896
|
)
|
|
|
(8,140
|
)
|
|
|
2,244
|
|
|
|
(28
|
)%
|
|
Interest income (expense), net
|
|
|
(1,725
|
)
|
|
|
(869
|
)
|
|
|
(856
|
)
|
|
|
99
|
%
|
|
Net loss and comprehensive loss
|
|
$
|
(7,621
|
)
|
|
$
|
(9,009
|
)
|
|
$
|
1,388
|
|
|
|
(15
|
)%
|
Research and Development Expenses
Research and development (R&D) expenses decreased to $2.1 million for the three months ended September 30, 2026 from $4.6 million for the three months ended September
30, 2025. The decrease of $2.5 million was primarily attributable to a decrease of $1.6 million in clinical trial costs, a decrease of $0.3 million in manufacturing costs, a decrease of $0.4 million in personnel costs and a decrease of $0.2
million in stock-based compensation costs.
General and Administrative Expenses
General and administrative expenses increased to $3.8 million for the three months ended September 30, 2026 from $3.6 million for the three months ended September 30, 2025.
The increase of $0.2 million was primarily attributable to an increase of $0.3 million in professional fees, an increase of $0.1 million in personnel costs offset by a decrease of $0.2 million in stock based compensation costs.
Comparison of the Nine months September 30, 2026 and 2025
The following table summarizes the results of our operations for the nine months ended September 30, 2026 and 2025:
| |
|
Nine Months Ended
September 30,
|
|
|
Increase (Decrease)
|
|
| |
|
2026
|
|
|
2025
|
|
|
$ Amount
|
|
|
%
|
|
| |
|
(in thousands)
|
|
|
|
|
|
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses
|
|
$
|
8,774
|
|
|
$
|
14,620
|
|
|
$
|
(5,846
|
)
|
|
|
(40
|
)%
|
|
General and administrative expenses
|
|
|
10,140
|
|
|
|
10,249
|
|
|
|
(109
|
)
|
|
|
(1
|
)%
|
|
Total operating expenses
|
|
|
18,914
|
|
|
|
24,869
|
|
|
|
(5,955
|
)
|
|
|
(24
|
)%
|
|
Loss from operations
|
|
|
(18,914
|
)
|
|
|
(24,869
|
)
|
|
|
5,955
|
|
|
|
(24
|
)%
|
|
Interest income (expense), net
|
|
|
(5,807
|
)
|
|
|
(3,233
|
)
|
|
|
(2,574
|
)
|
|
|
80
|
%
|
|
Benefit from income taxes
|
|
|
-
|
|
|
|
1,170
|
|
|
|
(1,170
|
)
|
|
|
(100
|
)%
|
|
Net loss and comprehensive loss
|
|
$
|
(24,721
|
)
|
|
$
|
(26,932
|
)
|
|
$
|
2,211
|
|
|
|
(8
|
)%
|
Research and Development Expenses
Research and development expenses decreased to $8.8 million for the nine months ended September 30, 2026 from $14.6 million for the nine months ended September 30, 2025.
The decrease of $5.8 million was primarily attributable to a decrease of $3.8 million in clinical trial costs, a decrease of $1.5 million manufacturing and quality costs, a decrease of $0.8 million in personnel costs offset by an increase of $0.3
million in stock based compensation costs.
General and Administrative Expenses
General and administrative expenses decreased to $10.1 million for the nine months ended September 30, 2026 from $10.2 million for the nine
months ended September 30, 2025. The decrease of $0.1 million was primarily attributable to a decrease of $0.1 million in professional fees, decrease of $0.1 million in stock based compensation costs offset by an increase of $0.1 million in
personnel costs.
Benefit from Income Taxes
Income tax benefit was zero for the nine months ended September 30, 2026 and $1.2 million for the nine months ended September 30, 2025. The decrease of $1.2 million was due to us
having met the statutory $20 million lifetime cap on total cumulative value of NOLs sold, which makes us ineligible to continue participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss (NOL) program.
Liquidity and Capital Resources
In August 2022, we entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an
Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company could offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to
$50 million, or the Placement Shares, through or to the Agents, as sales agents or principals. Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, the Agents could sell the Placement Shares by any
method permitted by law deemed to be an “at the market” offering as defined in Rule 415 of the Securities Act of 1933, as amended, including, without limitation, sales made through The Nasdaq Capital Market or on any other existing trading market
for the Company’s common stock. The Agents were to use commercially reasonable efforts to sell the Placement Shares from time to time, based upon the Company’s instructions (including any price, time or size limits or other customary parameters
or conditions the Company may impose). The Company paid the Agents a commission equal to three percent (3%) of the gross sales proceeds of any Placement Shares sold through the Agents under the Sales Agreement, and the Company has also provided
the Agents with customary indemnification and contribution rights. The Company was not obligated to make any sales of its common stock under the Sales Agreement. The offering of Placement Shares pursuant to the Sales Agreement was to terminate
upon the earlier of (i) the sale of all Placement Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms.
In August 2024, we entered into an Amended and Restated At Market Issuance Sales Agreement, or the New Sales Agreement, with B. Riley Securities, Inc. and H.C. Wainwright
& Co., LLC, with terms that are substantially consistent with those included in the original Sales Agreement. The New Sales Agreement superseded and replaced the Sales Agreement.
During the three and nine months ended September 30, 2026, we sold 0 shares and 937,420 shares, respectively, of its common stock with a net value of $0 million and $0.8
million, respectively, pursuant to the New Sales Agreement. During the three and nine months ended September 30, 2025, the Company sold 1,072,080 and 2,237,941 shares, respectively, of its common stock with a net value of $1.3 and $3.0 million,
respectively, pursuant to the New Sales Agreement. The New Sales Agreement was terminated on May 1, 2026.
In June 2026, we entered into a Sales Agreement, or the June 2026 Sales Agreement with Yorkville Securities, LLC and B. Riley Securities, Inc., with terms that are substantially
consistent with those included in the New Sales Agreement. During the three and nine months ended September 30, 2026, the Company sold 31,788,753 and 31,894,906 shares of common stock, respectively, for a net value of $12.64 million and $12.74
million, respectively, pursuant to the June 2026 Sales Agreement.
In August 2022, we entered into a venture loan and security agreement, or the Loan and Security Agreement, with Horizon Technology Finance Corporation, as lender and
collateral agent for itself and the other lenders. In total, the Company received $24.6 million in net proceeds under the Loan and Security Agreement. Our indebtedness under the Loan and Security Agreement was satisfied in full and retired in
full with a portion of the proceeds received from the Securities Purchase Agreement, as discussed below.
In January and February of 2025, we received approximately $1.2 million from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant our
participation in the New Jersey Technology Business Tax Certificate Transfer NOL program for tax year 2023.
In February 2025, we entered into a securities purchase agreement with certain purchasers, pursuant to which we agreed to sell an aggregate of 6,396,787 shares of common stock,
pre-funded warrants to purchase up to an aggregate of 933,334 shares of common stock, and common stock warrants to purchase up to an aggregate of 7,330,121 shares of common stock at a combined purchase price of $1.50 per share and warrant, or the
“February 2025 Offering”. Two of our directors participated in the February 2025 Offering and purchased 30,121 shares of common stock in the aggregate at an offering price per share of $1.66 and common stock warrants to purchase 30,121 shares of
common stock. The common stock warrants issued to our directors have an exercise price per share of $1.53 but are otherwise identical to the common stock warrants issued to all other participants in the February 2025 Offering. Aggregate gross
proceeds from the February 2025 Offering were approximately $11 million. Net proceeds to us from the February 2025 Offering, after deducting the placement agent fees and other estimated offering expenses payable by us, were approximately $10.05
million. The February 2025 Offering closed on February 28, 2025.
On April 30, 2025, we entered into a securities purchase agreement, or the “Securities Purchase Agreement” with certain third-party lenders and JGB Collateral LLC, as
collateral agent. Pursuant to the Securities Purchase Agreement, we agreed to sell (i) senior secured convertible debentures in an aggregate principal amount of $22,222,222 (collectively, the “Debentures”) and (ii) warrants to purchase up to
1,000,000 shares of common stock, for an exercise price of $2.52 per share (collectively, the “Warrants”), subject to adjustments as set forth in the Warrants, for a total purchase price of $20,000,000. Approximately $19 million of the proceeds
from the transactions contemplated by the Securities Purchase Agreement were used to satisfy in full and retire our indebtedness under the Loan and Security Agreement. On April 30, 2026, the Company delivered a redemption notice pursuant to which
it irrevocably elected to prepay, for cash, all of the outstanding principal amount under each of the Debentures issued pursuant to the Securities Purchase Agreement. On June 15, 2026, the Company paid the applicable redemption amount, equal to
103% of the principal amount outstanding plus all accrued and unpaid interest and all other amounts payable thereunder, and, upon such payment, each Debenture was redeemed in full and is of no further force or effect.
In November 2025, we entered into a securities purchase agreement with certain purchasers, pursuant to which we agreed to sell an aggregate of 5,741,000 shares of common stock, pre-funded warrants
to purchase up to an aggregate of 59,000 shares of common stock, and common stock warrants to purchase up to an aggregate of 5,800,000 shares of common stock (the “November 2025 Offering”). The offering price per share of common stock was $0.91
and the purchase price of each pre-funded warrant was $0.9099. Each common warrant issued in connection with the November 2025 Offering had an exercise price of $1.00 per share, can be exercised six months after the date of issuance and will expire
five years thereafter. Aggregate gross proceeds from the November 2025 Offering were $5.3 million. Net proceeds to the Company from the offering, after deducting the placement agent fees and other estimated offering expenses payable by the Company,
were approximately $4.8 million. In addition, in connection with the November 2025 Offering, we entered into a warrant amendment agreement pursuant to which we agreed, effective upon closing of the November 2025 Offering, to amend certain existing
warrants to purchase up to an aggregate of 5,948,334 shares of common stock at an exercise price of $1.50 per share, so that the amended warrants will have a reduced exercise price of $1.00 per share effective upon the closing of the November 2025
Offering and will be exercisable beginning on the date that is six (6) months after the closing of the November 2025 Offering. The November 2025 Offering closed on November 12, 2025.
On April 30, 2026, we entered into a securities purchase agreement (the “April 2026 Securities Purchase Agreement”) with YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”).
Pursuant to the securities purchase agreement, we agreed to issue and sell to the Investor and the Investor agreed to purchase from the Company (i) a promissory note in an aggregate principal amount of $6,000,000 (the “Promissory Note”) and (ii) a
warrant to purchase up to 2,158,274 shares of our Common Stock, par value $0.00033 per share, at an exercise price of $1.1824 per share, subject to adjustments (the “Warrant”). In addition, on June 15, 2026, in connection with the transactions
contemplated by the April 2026 Securities Purchase Agreement, we issued the Promissory Note and the Warrant to the Investor, we and the Investor entered into the Registration Rights Agreement and PDS Operating Corporation, a Delaware corporation
and wholly owned subsidiary of the Company and the Investor entered into a Guaranty Agreement.
On June 15, 2026, we entered into a Sales Agreement (the “June 2026 Sales Agreement”) with Yorkville Securities, LLC, an affiliate of the Investor (“Yorkville Securities”), and B. Riley Securities,
Inc. (“B. Riley Securities,” each of Yorkville Securities and B. Riley Securities individually an “Agent” and collectively, the “Agents”), with respect to an “at-the-market” offering program pursuant to which we may offer and sell, from time to
time at our sole discretion, shares of our Common Stock (the “Placement Shares”) having an aggregate offering price of up to $50,000,000 through or to the Agents, as sales agents or principals. During the three
months and nine months ended September 30, 2026, we sold 31,788,753 and 31,894,906 shares of common stock, respectively, for a net value of $12.64 and $12.74 million, respectively, pursuant to the June 2026 Sales Agreement.
On September 7, 2026, we entered into a securities purchase agreement (the “September 2026 Purchase Agreement”) with certain accredited investors,
including Nant Capital, LLC (”Nant”) and AB Group Ltd. (“AB Group”), providing for a private placement consisting of an initial closing and a contingent milestone closing (the “September 2026 Private Placement”). By virtue of its significant
post-transaction equity and warrant holdings and its contractual board designation rights described below, Nant is considered a related party of the Company in accordance with ASC Topic 850, Related Party Disclosures. At the initial closing on September 14, 2026, we issued 16,502,870 shares of common stock, pre-funded warrants to purchase up to 23,498,156 shares of common stock (the “September Pre-Funded Warrants”),
and common stock warrants to purchase up to 20,000,514 shares of common stock (the “September Common Warrants”), for aggregate gross proceeds of approximately $11.3 million. Each unit consisting of one share of common stock and an accompanying
warrant to purchase one-half of one share of common stock was sold for $0.2825. Each unit consisting of one September Pre-Funded Warrant and an accompanying warrant to purchase one-half of one share of common stock was sold for $0.28217. The
September Pre-Funded Warrants have an exercise price of $0.00033 per share and remain exercisable until exercised in full. They are subject to a nonwaivable 19.99% beneficial ownership limitation. The September Common Warrants have an exercise
price of $0.22 per share, are exercisable from issuance through the first anniversary of issuance and are subject to the nonwaivable 19.9% beneficial ownership limitation. The September Common Warrants also provide for cashless exercise under
certain circumstances and permit holders to receive pre-funded warrants in lieu of common stock when the beneficial ownership limitation prevents the issuance of common shares.
The contingent milestone closing is triggered upon the Company’s submission to the U.S. Food and Drug Administration of a registrational Phase 3 clinical trial protocol for PDS0301
designed in collaboration with Nant, subject to satisfaction or waiver of applicable closing conditions. Nant and AB Group are obligated to invest an additional $10 million and $1 million, respectively, at a price of $0.22 per share of common stock
or $0.21967 per pre-funded warrant. Under the September 2026 Purchase Agreement, Nant has the right to designate two directors while it beneficially owns at least 15% of our outstanding common stock and one director while it beneficially owns at
least 5% of the Company’s outstanding common stock, subject to the September 2026 Purchase Agreement. These board appointment rights confer significant influence over the Company’s governance, operating policies, and strategic clinical directions.
We also entered into a registration rights agreement with the investors and an option agreement with NantWorks, LLC as described in Note 9.
As of September 30, 2026, we had $15.2 million in cash and cash equivalents. Our primary uses of cash are operating expenses, primarily research and development expenditures and general and administrative expenses.
Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.
We evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year
beyond the filing of this Quarterly Report on Form 10-Q in accordance with ASC Subtopic 205-40, Going Concern. Since inception, we have had no revenue, have
experienced net losses and negative operating cash flows, and expect to continue to incur operating losses for the foreseeable future. In previous periods, and as recently as the quarter ended June 30, 2026, we had determined that substantial
doubt existed about our ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements. However, following completion of the September 2026 Private Placement, exercise of
additional warrants, and our cost-reduction initiatives, we believe our cash and cash equivalents will be sufficient to fund our current operating plan for at least the next 12 months from the date of issuance of these condensed consolidated
financial statements and as such substantial doubt has been alleviated.
We received approximately $11.3 million in gross proceeds at the initial closing of the September 2026 Private Placement, repaid the Yorkville promissory note on September 14, 2026,
and received additional proceeds from the existing at-the-market facility ($0.7million) and the exercise of outstanding warrants ($3.9 million) in November 2026 (See Note 15), which mitigated our funding needs. We also implemented certain
cost-saving initiatives, including the reduction of research and development expenses related to ending our Phase 3 clinical trial with PDS0101, as well as certain general and administrative expenses. While the contingent milestone closing
contemplated under the September 2026 Private Placement is expected to occur in advance of the December 31, 2026 fiscal year-end, this is not within our control and therefore, were the milestone not to be achieved, we intend to pause
our research and development activities until additional financing is obtained.
We expect to continue to fund our operations through available cash, additional equity or debt financing, collaborations, strategic alliances or license agreements. However, there can be no
assurance that the milestone and applicable conditions will be satisfied or that other financing will be available when needed on acceptable terms. If sufficient funding is not available, we may be required to delay, reduce or discontinue
development programs or other operations.
Cash Flows
The following table shows a summary of our cash flows for each of the periods indicated (in thousands):
| |
|
Nine Months Ended
September 30,
|
|
| |
|
2026
|
|
|
2025
|
|
Net cash used in operating activities
|
|
$
|
(15,388
|
)
|
|
$
|
(24,049
|
)
|
|
Net cash provided by financing activities
|
|
|
3,921
|
|
|
|
8,558
|
|
|
Net decrease in cash and cash equivalents
|
|
$
|
(11,467
|
)
|
|
$
|
(15,491
|
)
|